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ABBREVIATIONS AND INITIALISMS 
 
Abbreviation/Initialism Full name 
ANOVA Analysis of Variance 
DINL Diagnostic Ion/Neutral Loss 
EtOH Ethanol 
EtOAc Ethyl Acetate 
ECD Electrochemical Detection 
FA Formic Acid 
GC Gas Chromatography 
HMDS Hexamethyldisilazane 
HPLC High Performance Liquid Chromatography 
HRESIMS High Resolution Electrospray Ionization MS 
HMBC 
1
H Detected Heteronuclear Multiple Bond Correlation 
HSQC 
1
H Detected Heteronuclear Single Quantum Coherence 
IC50 Half Maximal Inhibitory Concentration 
IS Internal Standard 
IR Infrared Absorption Spectrum 
LOD Limit of Detection 
LOQ Limit of Quantification 
LC Liquid Chromatography 




MS Mass Spectrometry 
MPLC Medium Pressure Liquid Chromatography 
MO Magnolia officinalis Rehd. et Wils. 
MOB Magnolia officinalis Rehd. et Wils. var. biloba Rehd. et Wils. 
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Abbreviation Full name 
MOC Magnoliae Officinalis Cortex 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect Spectrometry 
OR Optical Rotation 
PNP p-Nitrophenol 
PNPG p-Nitrophenyl-α-D-glucopyranoside 
PhGs Phenylethanoid Glycosides 
PCA Principal Component Analysis 
PLS-DA Partial Least Squares Discriminant Analysis 
QTOF/MS Quadrupole Time of Flight Mass Spectrometry 
Rs  Resolution 
RSD Relative Standard Deviation 
SV Switching Valve 
S/N Signal-to-Noise Ratio 
TMCS Trimethylchlorosilane 
TCM Traditional Chinese Medicine 
TMH Total Content of Magnolol and Honokiol  
UV Ultraviolet Visible 
UHPLC Ultra-High Performance Liquid Chromatography 








Traditional Chinese medicine (TCM) has been used for an exceptionally long time, 
accumulating abundant clinical experience regarding the use of medicinal materials and 
appealing to a growing number of people in the world due to their green, health and hypotoxicity 
[1, 2]. Considering the fact that the TCMs and their preparations generally exert therapeutic 
effects based on active components [3], it is important to elaborate their material base and 
evaluate their quality. 
Magnoliae officinalis cortex (MOC) is recorded as a common medicine to regulate qi in the 
pharmacopoeia of the People's Republic of China (2020 edition), which can act to dry dampness, 
eliminate phlegm, and direct qi downward to eliminate fullness. The medicinal parts of stem, 
branch and root barks, usually used for the treatment of abdominal distention and pain, dyspepsia 
and asthmatic cough in clinic, are originated from Magnolia officinalis Rehd. et Wils. (MO) and 
M. officinalis Rehd. et Wils. var. biloba Rehd. et Wils. (MOB) [4]. 
In China, there are approximate 4,000 prescriptions containing MOC recorded in Prescription 
Dictionary of TCM [5]. What’s more, the State Administration of TCM of the People's Republic 
of China issued a list of Chinese classical prescriptions (first batch) in 2018, in which twelve 
prescriptions containing MOC were included. These classical prescriptions were the ones, 
showing significant clinic efficacy, handed down from generation to generation and experienced 
repeated clinical observation and verification for thousands of years. The prescriptions 
containing MOC, for instance, the famous Xiaochengqi Decoction (小承气汤) used to treat 
constipation caused by high fever, the Banxia Houpo Decoction (半夏厚朴汤) used to treat 
globus hysteriocus and the Houpo Qiwu Decoction (厚朴七物汤) used to treat persistent fever 
with abdominal distension, have been widely used in clinic in China. Besides the prescriptions 
used in clinic, MOC was also used alone to treat poor appetite, nausea, vomiting, intestine 
dryness and irregular menstruation. Modern pharmacological studies indicated that MOC had 
anti-spasmodic [6], cytotoxic [7] and antidiabetic activities [8]. And recently, bark extracts of 
MOB were allowed to be added as an ingredient to chewing gums and mints sold in the United 
States and approved as a new ingredient of food resource by the European Union [9]. 
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Phytochemical evaluations disclose that various chemical categories, including lignans, phenolic 
glycosides, phenylethanoid glycosides (PhGs), alkaloid and essential oil, were distributed in MO 
and MOB. Most researches focused on hydrophobic constituents of MOC, such as lignans, 
neolignans, alkaloids and sesquiterpenes [10-12], while no systematic work on hydrophilic 
constituents has been performed. In our previous work, two new PhGs [13], one new phenolic 
glycoside [14] and two other PhGs of magnolosides A, B [13] were reported, which indicated the 
existence of glycosides, especially PhGs, in MO. 
Most TCMs need to undergo a post-harvesting process to convert the raw material into a form 
readily useable for prescriptions. Traditionally, MOC is processed prior to clinical practice. In a 
previous work, some water-soluble compounds were described that changed after the MOC was 
processed [6].
 
Meanwhile, MOC is clinically used as an aqueous decoction, expecting that there 
are some water-soluble components related to the pharmacological activity. Subsequently, in an 
attempt to search for more bioactive substances from aqueous portion of MO, and to clarify its 
material foundation of efficacy, a systematic hydrophilic compounds study was performed, 
which resulted in characterization of ten PhGs (1-7, 12-14) and seven phenolic glycosides (8-11, 
15-17), among the above constituents, eleven compounds were found for the first time (Fig. 1.1). 
In addition, the α-glucosidase inhibitory effects and cytotoxic activities of the isolated aqueous 
compounds were presented herein. 
What’s more, in our preliminary study, the total PhGs in MOC showed evident efficacy in an 
animal model of gastrointestinal dysfunction, and further study indicated that magnoloside A, a 
main PhG in MOC, ameliorated functional dyspepsia rats by modulating of the secretion of 
related brain-gut peptides and altering the composition of intestinal microbiota [15]. All those 
suggested that the PhGs may contribute to the clinic effects of MOC. As such, it is necessary to 
develop a new chromatographic method to evaluate the quality of MOC based on the profiling of 
PhGs. PhGs compounds are known to be electrochemically active [16, 17], so that it is expected 
their sensitive detection in MOC can be performed by electrochemical detection (ECD). And the 
sensitivity of ECD is generally high enough to detect the low concentrations of magnolosides D, 
F, H, L, and M. Considering it is inevitable to take a long time to elute all analytes from a 
column in a single isocratic elution, multi-channel liquid chromatography with ECD (LC-ECD) 
is useful to shorten the measurement time and to keep sensitivity when the hydrophilic properties 
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of analytes are remarkably different [18, 19]. In the present study, a two-channel LC-ECD 
(2LC-ECD) was subsequently developed by newly designing the channel connection and the 
technique of employing an alternate rotation of one switching valve (SV). After the developed 
2LC-ECD method was validated, seven PhGs in different MOC samples were simultaneously 
determined with high sensitivity and analyzed by multivariable analysis. 
The hyphenations of different types of mass spectrometry (MS) with chromatography are the 
powerful tools for natural products characterization and many successful examples have been 
reported [20-30]. Based on the findings in chapter 1, not few compounds of PhG existed in MOC. 
PhGs were characterized by a phenethyl alcohol (C6-C2) moiety attached to a 
β-glucopyranose/β-allopyranose (core sugar) via a glycosidic bond and the core sugars are often 
abundantly decorated with substituents such as aromatic acids and various saccharides through 
ester or glycosidic linkages, respectively [31-35]. Considering the diversities of the saccharides, 
substituents and the substituted positions which lead to the luxuriant structures of PhGs, in this 
work, ultra-high performance liquid chromatography coupled with quadrupole time of flight MS 
(UHPLC-QTOF/MS), owning the virtues of accurate mass measurement, high throughput, 
MS/MS functions and supplying the guarantee of exact classification of ions, was applied to 
obtain rapid profiling of PhGs in MOC. And a method combining multiple diagnostic ion/neutral 
loss (DINL) post-analysis was proposed to characterize PhGs. By means of this method, 101 
PhGs were discovered from MOC. Meanwhile, 17 PhGs were unambiguously identified by 
comparing the retention time and MS/MS data with those of reference compounds.  
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Chapter 1  Isolation and Structural Characterization of Phenylethanoid Glycosides from 
Magnoliae Officinalis Cortex 
 
PhGs are a class of water-soluble compounds widely distributed in TCMs, as well as other 
medicinal plants. They have been detected in root, stem, leaf, flower, fruit and seed without 
organ selectivity. As their names suggest, PhGs are characterized by a phenethyl alcohol (C6-C2) 
moiety attached to a β-glucopyranose/β-allopyranosyl via a glycosidic bond. The core structures 
are often inundated with substituents such as aromatic acids (e.g. caffeic acid, coumaric acid, 
cinnamic acid, ferulic acid, and isoferulic acid) and various saccharides (e.g. rhamnose, xylose, 
apiose, glucose, lyxose, allose and arabinose) through ester or glycosidic linkages, respectively. 
The outstanding development of PhGs in diverse diseases proves their magnitude for medicinal 
chemistry research. To date, approximately 500 PhGs have been isolated and uncovered 
diversities of biological properties, including neuroprotective, anti-inflammatory, antioxidant, 
anti-aging, memory enhancement, antibacterial, antivirus, cytotoxic, immunomodulatory, and 
enzyme inhibitory effects [33]. 
Phytochemical evaluations disclose that there are lignans, phenolic glycosides, phenylethanoid 
glycosides (PhGs), alkaloid and essential oil, were distributed in MO and MOB. Most researches 
focused on hydrophobic constituents, such as lignans, neolignans, alkaloids and sesquiterpenes 
[10-12]. As described above, because MOC is clinically used as an aqueous decoction, some 
water-soluble components should have pharmacological activities. However, no systematic work 
on hydrophilic constituents is available to date. Based on the background, an attempt to search 
for more bioactive substances from aqueous portion of MO has been made to clarify its material 
basis of efficacy. The results showed that the structures of ten PhGs (M1-7, M12-14) and seven 
phenolic glycosides (M8-11, M15-17) were identified as hydrophilic constituents in MOC, in 
which eleven compounds were found for the first time (Fig. 1.1). 
 




1.1.1 Plant Material 
MO was collected from Enshi city, Hubei Province, People’s Republic of China, in May 2009, 
and identified by Prof. Bin Yang. A voucher specimen (NO. 20090518) is deposited in the 
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. 
 
1.1.2 Instrument 
Optical rotations were measured on an Automatic Polarimeter (Rudolph, USA). UV spectra 
were obtained in methanol (MeOH) on a Jasco V-650 spectrophotometer (JASCO). IR spectra 
were recorded in KBr pellets on a Bruker VERTEX70 (Bruker, Germany). HRESIMS were 




C nuclear magnetic 
resonance (NMR) spectra were taken on a Bruker AVIIIHD 600 spectrometer with the solvent 
peak used as references (Ettlingen, Germany). Medium pressure liquid chromatography (MPLC) 
was performed on an EZ Purifier II flash chromatography system (Shanghai Li Sui E-Tech CO. 
Ltd, Shanghai, China). Analytical HPLC was conducted on a Waters 2695 pump system 
equipped with a Waters 2996 photodiode array detector (Waters, Milford, MA, USA). 
Preparative HPLC was performed using a Waters 600 pump, equipped with a Waters 2487 
detector. GC was carried out on an Agilent 7890 GC system (Agilent, Santa Clara, CA, USA). 
Macroporous resin D101 (Tianjin, China), MCI CHP-20P column (50 × 600 mm, 75–150 μm, 
Mitsubishi Chemical Corp., Tokyo, Japan), C18 column (50 × 600 mm, 40–60 μm, YMC, Kyoto, 
Japan), Sephadex LH-20 (Pharmacia, Sweden) and semipreparative column (50 × 250 mm, 10 
μm, Agela) were used for column chromatography (CC) separations. 
 
1.1.3 Extraction and Isolation of Phenylethanoid Glycosides 
Stem barks (40 kg) were suspended in ethanol (EtOH):H2O (40 L, 70:30 v/v) with the bark 
material extracted by heating the suspension until reflux began (being held for 3h at this 
temperature), with this protocol being carried out a further 2×. The combined extracts were dried 
and then partitioned with ethyl acetate (EtOAc) (3 × 30 L). The water-soluble portion (20 L) was 
subjected to D101 macroporous resin CC eluted with EtOH:H2O (0:100 to 95:5), to obtain five 
fractions (Fr. 1–Fr. 5). Fr. 2 (550 g, EtOH:H2O (20:80)) was applied to an MCI CHP-20P column 
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eluted with EtOH:H2O (0:100 to 100:0) to yield four fractions (Fr. 2.1–Fr. 2.4). Fr. 2.2 (140 g, 
EtOH:H2O (20:80)) was subjected to MPLC with C18 CC to yield three major sub-fractions (Fr. 
2.2.1–Fr. 2.2.3). Fr. 2.2.2 was applied to Sephadex LH–20 CC, giving eight fractions (Fr. 
2.2.2.1–Fr. 2.2.2.8). Fr. 2.2.2.1 was purified by semi-preparative HPLC with MeCN:H2O 
containing 0.1% FA (15:85, v/v) as eluent, 60 mL/min, giving M8 (5.3 mg, tR = 32.85 min), M9 
(12.4 mg, tR = 27.18 min), M10 (56.0 mg, tR = 38.05 min), M11 (76.1 mg, tR = 34.69 min) and 
M16 (38.8 mg, tR = 48.00 min). Fr. 2.2.2.2 was subjected to semi-preparative HPLC to yield six 
fractions (Fr. 2.2.2.2.1–Fr. 2.2.2.2.6). Fr.2.2.2.2.5 was determined as compound M15 (39 mg, 
51.52 min). Fr. 2.2.2.2.1 was re-applied to the semi-preparative HPLC with MeOH:H2O 
containing 0.1% FA (35:65, v/v) as eluent, 60 mL/min, giving M7 (29.0 mg, tR = 23.26 min). 
Compound M6 was obtained from Fr. 2.2.2.2.6 by semi-preparative HPLC with MeCN:H2O 
containing 0.1% FA (15:85, v/v) as eluent. Fr. 2.2.2.3 was purified by semi-preparative HPLC 
with MeOH:H2O containing 0.1% FA (30:70, v/v) as eluent, 60 mL/min, giving M17 (372 mg). 
Fr. 2.2.2.5 was purified by semi-preparative HPLC with MeCN:H2O containing 0.1% FA (15:85, 
v/v) as eluent, 60 mL/min, giving M5 (7.0 mg, tR = 70.69 min). Fr. 2.3 (90 g, EtOH:H2O (25:75)) 
was subjected to C18 CC to yield three major subfractions (Fr. 2.3.1–Fr. 2.3.3). Fr. 2.3.1 was 
applied to Sephadex LH-20 CC, giving eight fractions (Fr. 2.3.1.1–Fr. 2.3.1.8). Fr. 2.3.1.4 was 
subjected to semi-preparative HPLC to yield four fractions (Fr. 2.3.1.4.1–Fr. 2.3.1.4.4), Fr. 
2.3.1.4.2 was purified by semi-preparative HPLC with MeCN:H2O containing 0.1% FA (12:88, 
v/v) as eluent, 60 mL/min, giving M1 (21.9 mg, tR = 75.50 min) and M2 (14.9 mg, tR = 87.68 
min). Fr. 2.3.1.4.3 was purified by semi-preparative HPLC with the same eluent, giving M3 
(39.0 mg, tR = 77.71 min). Fr. 2.3.1.5 was subjected to semi-preparative HPLC using MeOH:H2O 
containing 0.1% FA (25:75, v/v) as eluent, 60 mL/min to yield M4 (100 mg, tR = 64.61 min) and 
M13 (2.9 g, tR = 51.43 min). Fr. 2.4 (105 g, EtOH eluent) was subjected to C18 CC to yield four 
major sub-fractions (Fr. 2.4.1–Fr. 2.4.4). Fr. 2.4.3 was applied to Sephadex LH–20 CC, giving 
two fractions (Fr. 2.4.3.1–Fr. 2.4.3.2). Fr. 2.4.3.2 was subjected to semi-preparative HPLC with 
MeOH:H2O containing 0.1% FA (40:60, v/v) as eluent, 60 mL/min to yield M12 (206 mg, tR = 




1.2 Structural Characterization of Phenylethanoid Glycosides 
The water-soluble portion of the 70% (v/v) EtOH aqueous extract of the stem bark of MO was 
subjected to sequential CC over D101 macroporous resin, MCI CHP-20P, C18, and Sephadex 
LH-20, with purification using preparative HPLC to yield eleven novel glycosides, magnolosides 
I-M, O, P, V-X, Z (M1-11). In addition, six known ones, magnoloside E (M12) [13], 
magnoloside A (M13) [36], magnoloside D (M14) [13],
 





and 1,1'-dibenzene-6',8',9'-trihydroxy-3-allyl-4-O-β-D-glucopyranoside (M17) [39] 




C NMR and MS data were consistent with 
those reported in the literature. 
 
1.2.1 OR, IR, UV, NMR, HRMS Data of Phenylethanoid Glycosides 
 
1.2.1.1 Magnoloside I (M1) 
Pale yellow amorphous solid; [α]
20
D -54.1 (c 0.15, MeOH); UV (H2O) λmax (log ε) 290 (4.25), 





NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) spectroscopic data, see Tables 1.1 




; HRESIMS m/z 755.2377 [M-H]
-
 (calcd for 
C34H43O19, 755.2399). 
 
1.2.1.2 Magnoloside J (M2) 
Pale yellow amorphous solid, [α]
20
D +25.6 (c 0.08, MeOH); UV (H2O) λmax (log ε) 285 (4.16), 





NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) spectroscopic data, see Tables 1.1 




; HRESIMS m/z 799.2651 [M-H]
-
 (calcd for 
C36H47O20, 799.2661). 
  
1.2.1.3 Magnoloside K (M3) 
Pale yellow amorphous solid; [α]
20
D -59.5 (c 0.08, MeOH); UV (H2O) λmax (log ε) 290 (4.18), 







NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) spectroscopic data see Tables 1.1 
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; HRESIMS m/z 799.2650 [M-H]
-
 (calcd for 




H NMR spectroscopic data of compounds M13, M6 and M7 (600 MHz, pyridine-d5) 
Position M1 δH (J in Hz) M2 δH (J in Hz) M3 δH (J in Hz) M6 δH (J in Hz) M7 δH (J in Hz) 
2 7.28 d (1.8) 7.24 overlap 7.30 d (1.8) 7.19 d (1.8) 7.21 overlap 
5 7.19 d (7.8) 6.94 d (7.8) 7.20 overlap 7.15 d (7.8) 7.16 d (7.8) 
6 6.84 dd (7.8, 1.8) 6.86 d (7.8) 6.82 dd (7.8, 1.8) 6.75 dd (7.8, 1.8) 6.77 brd (7.8) 
β 3.12 m 3.07 t (7.2) 3.06 t (7.2) 3.01 m 3.01 m 
α 4.38 m 
3.86 dt (9.0, 7.2) 
4.40 overlap 




3.93 dt (9.0, 6.6) 
4.39 overlap 
3.94 dt (8.4, 7.8) 
All-1' 5.25 d (7.8) 5.24 d (8.4) 5.24 d (7.8) 5.39 d (7.8) 5.39 d (7.8) 
2' 4.19 dd (7.8, 3.0) 4.22 dd (7.8, 2.4) 4.58 overlap 4.05 dd (7.8, 3.0) 4.06 d (7.8) 
3' 6.38 t (3.0) 6.35 t (2.4) 6.38 t (3.0) 4.78 t (3.0) 4.79 brs 
4' 4.25 overlap 4.43 overlap 4.51 overlap 4.15 dd (9.0, 3.0) 4.19 brd (7.2) 
5' 4.54 overlap 4.52 m 4.50 overlap 4.69 ddd (9.0, 6.6, 
1.8) 
4.67 m 
6' 4.79 brd (10.2) 
4.33 overlap 
4.76 brd (10.8) 





5.24 d (11.4) 
4.97 dd (11.4, 6.0) 
Glc-1'' 5.08 d (7.8) 5.09 d (7.8) 5.08 d (7.8) 5.31 d (7.8) 5.28 d (7.2) 
2'' 4.10 t (8.4) 4.09 t (7.8) 4.08 t (8.4) 4.16 dd (9.0, 7.8) 4.12 t (7.2) 
3'' 4.27 overlap 4.28 overlap 4.26 overlap 4.24 t (9.0) 4.23 overlap 
4'' 4.28 overlap 4.39 overlap 4.41 overlap 4.30 t (9.0) 4.28 overlap 
5'' 3.93 m 3.94 m 3.93 m 3.84 ddd (9.0, 4.8, 
3.0) 
3.81 m 






4.48 dd (11.4, 3.0) 
4.40 dd (11.4, 4.8) 
4.44 d (10.8) 
4.37 overlap 
Rha/Api-1''' 5.96 s 5.75 s 5.77 s 6.07 d (1.2) 6.08 s 
2''' 4.62 overlap 4.29 overlap 4.57 overlap 4.94 m 4.76 brs 
3'''  4.53 overlap 4.58 overlap 4.95 m 4.83 dd (9.0, 1.8) 
4''' 4.60 d (9.6) 
4.34 s 
4.33 overlap 4.33 overlap 4.51 t (9.0) 4.49 t (9.0) 
5''' 4.40 overlap 
4.27 overlap 
4.76 overlap 4.76 overlap 4.90 m 4.27 overlap 
6'''  1.69 d (6.0) 1.66 d (6.0) 1.70 d (6.6) 1.62 d (6.0) 
2'''' 7.53 d (8.4) 7.52 s 7.29 d (1.2) 7.50 s 7.80 d (1.8) 
3'''' 7.17 d (8.4)     
5'''' 7.17 d (8.4) 7.22 overlap 7.20 overlap  7.41 d (8.4) 
6'''' 7.53 d (8.4) 7.07 d (7.2) 7.14 dd (7.8, 1.2) 7.50 s 7.89 dd (8.4, 1.8) 
7'''' 7.94 d (16.2) 7.92 d (15.6) 7.93 d (15.6)   
8'''' 6.71 d (16.2) 6.68 d (15.6) 6.77 d (15.6)   
OCH3  3.71 s 3.79 s 3.56 s 3.63 s 
 
1.2.1.4 Magnoloside L (M4) 
Pale yellow amorphous solid; [α]
20
D -82.4 (c 0.09, MeOH); UV (H2O) λmax (log ε) 290 (4.13), 







NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) spectroscopic data, see Table 1.3; 




; HRESIMS m/z 609.1817 [M-H]
-
 (calcd for C28H33O15, 
609.1819). 
 
1.2.1.5 Magnoloside M (M5) 
Pale yellow amorphous solid; For 
1
H NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, 
C5D5N) spectroscopic data, see Table 1.3; ESIMS m/z 623.1 [M-H]
-









C NMR spectroscopic data of compounds M13, M6 and M7 (150 MHz, pyridine-d5) 
Position M1 δC M2 δC M3 δC M6 δC M7 δC 
1 130.5 132.5 130.7 130.5 130.5 
2 117.6 117.6 117.7 117.5 117.5 
3 147.1 147.9 146.9 147.2 147.2 
4 145.6 147.2 145.6 145.6 145.6 
5 116.6 112.8 116.6 116.5 116.5 
6 120.6 120.3 120.8 120.4 120.5 
β 36.4 36.4 36.5 36.4 36.4 
α 71.4 71.4 71.6 71.5 71.43 
All-1
'
 100.5 100.6 100.6 102.3 102.4 
2
'
 72.0 72.5 72.1 72.5 72.4 
3
'
 70.7 70.5 70.5 73.0 73.0 
4
'
 66.6 66.5 66.4 69.7 69.4 
5
'
 75.2 75.1 75.1 73.1 73.1 
6
'
 69.8 69.7 69.6 66.2 65.8 
Glc-1
''
 105.7 105.7 105.8 106.9 106.7 
2
''
 75.3 75.2 75.2 76.5 76.3 
3
''
 78.4 78.3 78.3 78.5 78.5 
4
''
 71.6 71.5 71.7 71.4 71.3 
5
''
 78.6 78.5 78.5 78.6 78.6 
6
''
 62.7 62.6 62.6 62.6 62.6 
Rha/Api-1
'''
 106.4 98.1 98.0 103.3 100.4 
2
'''
 77.7 72.0 72.4 71.6 71.41 
3
'''
 80.8 72.4 72.6 72.3 72.3 
4
'''
 75.9 74.0 74.1 84.8 84.4 
5
'''
 66.7 69.8 69.7 69.5 69.3 
6
'''
  18.7 18.7 18.4 18.4 
1
''''
 126.1 126.9 126.5 126.6 125.1 
2
''''
 130.8 116.0 111.3 107.4 113.7 
3
''''
 116.8 147.5 148.9 153.7 150.2 
4
''''
 161.4 150.2 151.1 139.4 150.3 
5
''''
 116.8 116.6 116.6 153.7 116.7 
6
''''
 130.8 122.2 124.0 107.4 123.8 
7
''''
 145.3 146.0 145.7 166.3 166.5 
8
''''
 115.5 115.3 115.6   
9
''''
 167.4 167.5 167.5   
OCH3  56.0 55.9 55.9 55.8 
 
1.2.1.6 Magnoloside O (M6) 
White amorphous solid; [α]
20
D -75.5 (c 0.21, MeOH); UV (H2O) λmax (log ε) 268 (4.01) nm; 




H NMR (600 MHz, 
C5D5N) and 
13





; HRESIMS m/z 803.2599 [M-H]
-
 (calcd for C35H47O21, 
803.2610). 
 
1.2.1.7 Magnoloside P (M7) 
White amorphous solid; [α]
20
D -68.0 (c 0.21, MeOH); UV (H2O) λmax (log ε) 258 (4.22), 287 




H NMR (600 
MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) spectroscopic data, see Tables 1.1 and 1.2; 




; HRESIMS m/z 773.2513 [M-H]
-







H (600 MHz) and 
13
C NMR (150 MHz) spectroscopic data of compounds M4 and M5 in 
pyridine-d5 
Position 
        M4      M5 
δC δH (J in Hz) δC δH (J in Hz) 
1 130.3  130.7  
2 117.4 7.26 brs 117.7 7.27 d (1.8) 
3 146.9  147.7  
4 145.4  145.6  
5 116.3 7.20 d (7.8) 116.7 7.23 overlap 
6 120.4 6.81 brd (7.8) 120.7 6.77 dd (8.4, 1.8) 
β 36.2 3.12 m 36.5 3.06 t (7.8) 
α 71.1 4.33 overlap 
3.90 m 
71.6 4.33 m 
3.86 dt (9.6, 6.6) 
All-1
'
 100.4 5.31 d (7.8) 100.4 5.53 d (7.8) 
2
'
 72.2 4.33 overlap 74.0 4.70 dd (7.8, 3.0) 
3
'
 70.7 6.50 brs 65.7 5.25 t (3.0) 
4
'
 66.7 4.45 overlap 70.6 5.62 dd (10.2, 3.0) 
5
'
 76.4 4.45 overlap 73.5 4.74 ddd (10.2, 4.8, 1.8) 
6
'
 62.2 4.49 overlap 
4.36 overlap 
62.0 4.30 overlap 
4.18 dd (12.0, 4.8) 
Rha/Api-1
''
 106.3 6.06 brs 97.7 5.72 brs 
2
''
 77.4 4.66 brs 72.5 4.61 brs 
3
''
 80.6  72.7 4.31 overlap 
4
''
 75.7 4.32 overlap 74.1 4.28 overlap 
5
''
 66.4 4.39 overlap 
4.28 d (11.4) 
69.8 4.80 m 
6
''
   18.7 1.67 d (6.6) 
1
'''
 126.7  126.8  
2
'''
 115.8 7.54 brs 115.9 7.54 s 
3
'''
 147.4  147.0  
4
'''
 150.2  150.6  
5
'''
 116.4 7.21 overlap 116.6 7.23 overlap 
6
'''
 121.9 7.10 brd (8.4) 122.2 7.10 dd (7.8, 1.8) 
7
'''
 145.7 7.98 d (15.6) 146.3 7.95 d (16.2) 
8
'''
 115.2 6.73 d (15.6) 114.7 6.56 d (16.2) 
9
'''
 167.3  166.8  
 
1.2.1.8 Magnoloside V (M8) 
White amorphous solid; For 
1
H NMR (600 MHz, C5D5N) and 
13
C NMR (150 MHz, C5D5N) 




; HRESIMS m/z 
817.2749 [M-H]
-
 (calcd for C36H49O21, 817.2766). 
 
1.2.1.9 Magnoloside W (M9) 
White amorphous solid; [α]
20
D -20.8 (c 0.10, MeOH); UV (H2O) λmax (log ε) 256 (4.48), 293 




H NMR (600 
MHz, C5D5N) and 
13





. HRESIMS m/z 787.2666 [M-H]
-
 (calcd for C35H47O20, 787.2661).  
 
1.2.1.10 Magnoloside X (M10) 
Pale yellow amorphous solid; [α]
20
D -86.7 (c 0.15, MeOH); UV (H2O) λmax (log ε) 266 (3.88) 
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H NMR (600 
MHz, D2O) and 
13
C NMR (150 MHz, D2O) spectroscopic data, see Table 1.4; ESIMS m/z 674.2 
[M+NH4]
+
; HRESIMS m/z 701.2317 [M+HCOO]
-




H (600 MHz) and 
13











δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) 
1 157.0  157.2  157.6  157.7  
2,6 116.5 7.27 d (9.0) 116.8 7.28 d (8.4) 119.2 6.91 d (7.8) 119.2 6.91 d (8.4) 
3,5 130.8 7.31 d (9.0) 131.0 7.34 d (8.4) 133.1 6.88 d (7.8) 133.1 6.89 d (8.4) 
4 133.7  133.9  135.5  135.3  
7 40.1 3.11 dd (13.2, 5.4) 
2.97 dd (13.2, 7.8) 
40.3 3.10 dd (13.8, 4.8) 
2.97 dd (13.8, 7.8) 
40.8 2.66 dd (13.8, 4.8) 
2.54 dd (13.8, 7.8) 
40.9 2.65 dd (13.8, 5.4) 
2.54 dd (13.8, 7.8) 
8 73.8 4.28 overlap 74.0 4.29 overlap 75.6 3.54 t (9.6) 75.6 3.78 overlap 
9 66.5 4.01 dd (10.8, 4.2) 
3.96 dd (10.8, 6.0) 
66.8 4.02 dd (11.4, 4.8) 
3.97 dd (11.4, 6.6) 
67.7 3.56 overlap 
3.43 dd (10.8, 7.2) 
67.6 3.56 overlap 
3.41 dd (11.4, 6.6) 
All-1
'
 100.2 6.01 d (7.8) 100.3 6.00 d (7.8) 100.7 5.30 d (7.8) 100.6 5.31 d (7.8) 
2
'
 71.8 4.30 overlap 72.4 4.33 overlap 73.8 4.29-4.25 overlap 73.9 4.28 overlap 
3
'
 72.8 4.87 s 73.3 4.29 overlap 73.0 3.82-3.76 overlap 72.9 3.80 overlap 
4
'
 69.2 4.23 overlap 69.4 4.23 overlap 70.7 3.82-3.76 overlap 70.6 3.80 overlap 
5
'
 73.1 4.87 overlap 73.1 4.86 overlap 74.5 4.29-4.25 overlap 74.4 4.28 overlap 
6
'
 65.9 5.35 d (10.8) 
4.93 overlap 
65.7 5.31 d (11.4) 
4.90 dd (11.4, 7.2) 
67.6 4.66 brd (11.4) 
4.57 dd (11.4, 8.4) 
67.3 4.63 brd (11.4) 
4.54 dd (11.4, 8.4) 
Rha/All-1
''
 103.1 6.11 s 100.4 6.16 s 104.7 5.40 s 101.6 5.62 s 
2
''
 71.4 4.95 overlap 71.4 4.78 s 72.9 4.03 brd (9.6) 72.6 4.25 overlap 
3
''
 72.2 4.31 overlap 72.0 4.32 overlap 73.3 4.26 overlap 73.0 4.05 dd (9.6, 2.4) 
4
''
 84.6 4.51 t (9.0) 84.4 4.49 dd (9.6, 9.0) 74.3 3.79 overlap 74.7 3.56 dd (9.6, 6.6) 
5
''
 69.5 4.22 overlap 69.3 4.23 overlap 72.8 4.29-4.25 overlap 72.7 3.80 overlap 
6
''
 18.2 1.72 d (6.0) 18.4 1.65 d (6.0) 19.5 1.26 d (6.0) 19.6 1.26 d (6.0) 
Glc-1
'''
 106.7 5.30 d (7.8) 106.7 5.28 d (7.8)     
2
'''
 76.3 4.17 dd (9.0, 7.8) 76.3 4.13 t (8.4)     
3
'''
 78.3 4.29 overlap 78.5 4.22 t (9.0)     
4
'''
 71.2 4.31 overlap 71.3 4.33 t (9.0)     
5
'''
 78.4 3.83 m 78.6 3.80 ddd (9.0, 4.8, 2.4)     
6
'''
 62.4 4.47 dd (11.4, 1.2) 
4.40 dd (11.4, 4.2) 
62.6 4.44 dd (12.0, 2.4) 
4.38 dd (12.0, 4.8) 
    
1
''''
 126.3  125.0  128.8  126.9  
2
''''
 107.3 7.51 s 113.9 7.80 d (1.8) 110.0 7.27 s 116.3 7.50 s 
3
''''
 153.5  150.4  155.4  151.8  
4
''''
 139.3  150.6  140.5  151.7  
5
''''
 153.5  116.9 7.53 d (8.4) 155.4  119.0 7.25 d (8.4) 
6
''''
 107.3 7.51 s 123.9 7.91 dd (8.4, 1.8) 110.0 7.27 s 126.7 7.60 brd (8.4) 
7
''''
 166.0  166.3  170.0  170.2  
OCH3 55.9 3.60 s 56.0 3.67 s 59.0 3.83 s 58.8 3.80 s 
a Recorded in pyridine-d5 
b Recorded in D2O 
 
1.2.1.11 Magnoloside Z (M11) 
Pale yellow amorphous solid; [α]
20
D -89.0 (c 0.15, MeOH); UV (H2O) λmax (log ε) 256 (4.08), 




H NMR (600 MHz, D2O) 
and 
13







 (calcd for C30H39O17, 671.2187).  
 
1.2.2 Sugar Hydrolysis Data of Phenylethanoid Glycosides 
Compounds M3, M4, M6, M7 and M9-11 (each 2.0 mg) were individually hydrolyzed with 
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10 mM NaOH (1 mL) at 60°C for 2 h. Each solution was neutralized and extracted with EtOAc 
(3 × 1 mL). 2 M CF3CO2H (2 mL) was added to the aqueous layer and heated at 110°C for 3 h. 
After cooling to room temperature, each solution was extracted with EtOAc (3 × 2 mL). Each 
aqueous layer was then dried by a stream of N2. The residue and standard D/L-glucose, D-allose, 
D-apiose and L-rhamnose were individually dissolved in anhydrous pyridine (100 μL), and 
L-cysteine methyl ester hydrochloride (0.06 M, 100 μL) was added. The mixture was stirred at 
60°C for 1 h, then 150 μL of HMDS-TMCS (hexamethyldisilazane-trimethylchlorosilane 1:1) 
was added, and the mixture was stirred at 60°C for 30 min. The precipitate was removed by 
centrifugation (10000 rpm, 10 min), and the supernatant was analyzed by GC using an HP-5 
column (30 m × 0.32 mm, 0.25 μm). Temperatures of the injector and detector were both at 
250°C. The temperature of the oven was 230°C for 30 min. Derivatives of L-rhamnose (9.147 
min), D/L-glucose (13.088/13.758 min), D-apiose (7.522 min), and D-allose (13.752 min) were 




Fig. 1.1 Structures of M1–17. (New compounds were marked with “*”.) 
 
1.2.3 Identification of Phenylethanoid Glycosides 
Magnoloside I (M1) was isolated as a pale yellow amorphous powder, and its molecular 
formula was C34H44O19 based on high resolution electrospray ionization MS (HRESIMS) data at 
m/z 755.2377 [M-H]
- 
(calcd for C34H43O19, 755.2399). The ultraviolet visible (UV) spectrum 
showed absorption maxima at 288 and 330 nm. Its infrared absorption (IR) spectrum displayed 
absorption bands of hydroxy (3415 cm
-1





) groups. The 
1
H NMR spectrum of M1 exhibited characteristic signals 
belonging to trans-p-coumaroyl and 3,4-dihydroxyphenylethanol moieties: typical trans-olefinic 
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protons at δH 7.94 (1H, d, J = 16.2 Hz, H-7''''), 6.71 (1H, d, J = 16.2 Hz, H-8''''), and AA'BB'-type 
aromatic protons at δH 7.53 (2H, d, J = 8.4 Hz, H-2'''', 6''''), 7.17 (2H, d, J = 8.4 Hz, H-3'''', 5''''); a 
set of ABX-type aromatic signals at δH 7.28 (1H, d, J = 1.8 Hz, H-2), 7.19 (1H, d, J = 7.8 Hz, 
H-5), 6.84 (1H, dd, J = 7.8, 1.8 Hz, H-6) and a β-methylene at δH 3.12 (2H, m, H-β) (Table 1.1). 
Additionally, three anomeric proton resonances appeared at δH 5.25 (1H, d, J = 7.8 Hz, H-1'), 
5.08 (1H, d, J = 7.8 Hz, H-1''), and 5.96 (1H, s, H-1'''), which correlated, respectively, with 
signals at δC 100.5, 105.7, and 106.4 in the 
1
H detected heteronuclear single quantum coherence 
(HSQC) spectrum. A series of signals in the 
1
H NMR spectrum at δH 5.25 (1H, d, J = 7.8 Hz, 
H-1'), 4.19 (1H, dd, J = 7.8, 3.0 Hz, H-2'), 6.38 (1H, t, J = 3.0 Hz, H-3'), 4.25 (1H, overlap), 4.54 
(1H, overlap), 4.79 (1H, brd, J = 10.2 Hz, H-6a') and 4.33 (1H, overlap, H-6b') indicated a rare 
β-allopyranosyl unit in the structure of M1. This was confirmed by comparing its NMR features 










which all contained an 
allopyranose moiety. Another series of signals in the 
1
H NMR spectrum at δH 5.08 (1H, d, J = 7.8 
Hz, H-1''), 4.10 (1H, t, J = 8.4 Hz, H-2''), 4.27 (1H, overlap, H-3''), 4.28 (1H, overlap, H-4''), 
3.93 (1H, m, H-5''), 4.53 (1H, overlap, H-6a''), and 4.40 (1H, overlap, H-6b'') indicated the 
existence of a β-glucopyranosyl moiety. Comparison of the 
1
H NMR data of M1 with those of 
magnoloside H indicated that the caffeoyl moiety in magnoloside H was replaced by a 
trans-p-coumaroyl group in M1 [41]. Finally, all connectivities within M1 were established by 
an 
1
H detected heteronuclear multiple bond correlation (HMBC) experiment: H-1' (δH 5.25, 
allose)/α-C (δC 71.4, phenylethanol), H-3' (δH 6.38, allose)/C-9'''' (δC 167.4, coumaroyl), H-2' (δH 
4.19, allose)/C-1''' (δC 106.4, apiose), H-1'' (δH 5.08, glucose)/C-6' (δC 69.8, allose). Thus, 
structure M1 was elucidated as 2-(3,4-dihydroxyphenyl)-ethyl 
1-O-[3-O-coumaroyl-2-O-β-D-apiofuranosyl-6-O-β-D-glucopyranosyl]-β-D-allopyranoside. 
Magnolosides J (M2) and K (M3) were isolated as pale yellow amorphous powders, having 
the same molecular formula of C36H48O20 based on HRESIMS m/z 799.2651 [M-H]
-
 (calcd for 
C36H47O20, 799.2661) and 799.2650 [M-H]
-
 (calcd for C36H47O20, 799.2661), respectively. There 
were also two sets of ABX-type aromatic signals, two trans-olefinic protons and a β-methylene 
group detected in the 
1
H NMR spectra of M2 and M3 (Table 1.1), indicating the existence of 
(E)-caffeoyl and 3,4-dihydroxyphenylethanol moieties. Additionally, a methoxy group signal 
appeared at δH 3.71 (3H, s) in M2 and 3.79 (3H, s) in M3, and three anomeric proton resonances 
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were observed at δH 5.24 (1H, d, J = 8.4 Hz, H-1'), 5.09 (1H, d, J = 7.8 Hz, H-1''), 5.75 (1H, s, 
H-1''') in M2 and δH 5.24 (1H, d, J = 7.8 Hz, H-1'), 5.08 (1H, d, J = 7.8 Hz, H-1''), 5.77 (1H, s, 
H-1''') in M3, respectively. The methyl signal at δH 1.69 (3H, d, J = 6.0 Hz) in M2 and δH 1.66 
(3H, d, J = 6.0 Hz) in M3 indicated the existence of a rhamnose group. Comparison of the NMR 
data of M2 with those of magnoloside F suggested one hydroxy in a phenylethanol moiety in 
magnoloside F being replaced by a methoxy group in M2 [41]. In the HMBC spectrum, 
cross-peaks were observed between the protons of methoxy (δH 3.71) and C-4 (δC 147.2), H-6 
(δH 6.86) and C-4 (δC 147.2), which showed that the methoxy was linked to C-4. Therefore, M2 
was assigned as 2-(3-hydroxy-4-methoxyphenyl)-ethyl 
1-O-[3-O-caffeoyl-2-O-α-L-rhamnopyranosyl-6-O-β-D-glucopyranosyl]-β-D-allopyranoside.  
Compared to the NMR spectra of M2, the differences in those of M3 suggested that the 
caffeoyl moiety in M2 was replaced by a trans-feruloyl group in M3, i.e., the methoxy was 
linked to C-3'''' of a caffeoyl group. This assumption was confirmed by an HMBC correlation 
between δH 3.79 (3H, s) and C-3'''' (δC 148.9). Further evidence was obtained by comparing the 
NMR data of M3 with those of cistanoside J [42].
 
So M3 was deduced to be 
2-(3,4-dihydroxyphenyl)-ethyl 
1-O-[3-O-feruloyl-2-O-α-L-rhamnopyranosyl-6-O-β-D-glucopyranosyl]-β-D-allopyranoside. 
Magnolosides L (M4) and M (M5), respectively, were assigned the molecular formulae of 
C28H34O15 and C29H36O15 deduced from HRESIMS m/z 609.1817 [M-H]
- 
(calcd for C28H33O15, 
609.1819) and 623.1979 [M-H]
-
 (calcd for C29H35O15, 623.1976), respectively. The 
1
H NMR data 
of M4 (Table 1.3) also indicated there were two sets of ABX-type aromatic signals: δH 7.26 (1H, 
brs), 7.20 (1H, d, J = 7.8 Hz), 6.81 (1H, brd, J = 7.8 Hz) and δH 7.54 (1H, brs), 7.21 (1H, 
overlap), 7.10 (1H, brd, J = 8.4 Hz); two trans-olefinic protons δH 7.98 (1H, d, J = 15.6 Hz) and 
6.73 (1H, d, J = 15.6 Hz); β-methylene δH 3.12 (2H, m) and two anomeric protons δH 5.31 (1H, d, 
J = 7.8 Hz, H-1') and 6.06 (1H, brs), respectively. Comparison with the NMR data of 
magnoloside G and M4, indicated that in the latter there were allose and apiose moieties [41]. In 
the HMBC spectrum, correlations of H-1' (δH 5.31, allose)/α-C (δC 71.1, phenylethanol), H-3' (δH 
6.50, allose)/C-9''' (δC 167.3, caffeoyl), and H-1'' (δH 6.06, apiose)/C-2' (δC 72.2, allose) were also 






H NMR data of compound M5 also indicated the existence of two sets of ABX-type 
aromatic signals, two trans-olefinic protons, a β-methylene and two anomeric protons. The 
methyl signals at δH 1.67 (3H, d, J = 6.6 Hz) indicated the existence of rhamnose. Cross-peaks of 
H-1' (δH 5.53, allose)/α-C (δC 71.6, phenylethanol), H-4' (δH 5.62, allose)/C-9''' (δC 166.8, 
caffeoyl), and H-1'' (δH 5.72, rhamnose)/C-2' (δC 74.0, allose) were observed in HMBC. Thus, 
M5 was proposed as a 2-(3,4-dihydroxyphenyl)-ethyl 
1-O-[4-O-caffeoyl-2-O-α-L-rhamnopyranosyl]-β-D-allopyranoside. 
Magnolosides O (M6) and P (M7), obtained as white amorphous powders, displayed 
molecular formulae of C35H48O21 and C34H46O20 based on HRESIMS m/z 803.2599 [M-H]
-
 
(calcd for C35 H47 O21, 803.2610) and 773.2513 [M-H]
-
 (calcd for C34H45O20, 773.2504), 
respectively. The 
1
H NMR spectra of M6 and M7 exhibited a set of ABX-type aromatic signals 
and a β-methylene moiety, which indicated the existence of a 3,4-dihydroxyphenylethanol group 
(Table 1.1). There were also three anomeric proton resonances at δH 5.39 (1H, d, J = 7.8 Hz, 
H-1'), 5.31 (1H, d, J = 7.8 Hz, H-1''), and 6.07 (1H, d, J = 1.2 Hz, H-1''') in M6 and δH 5.39 (1H, 
d, J = 7.8 Hz, H-1'), 5.28 (1H, d, J = 7.2 Hz, H-1''), and 6.08 (1H, s, H-1''') in M7, respectively. 
The methyl signal at δH 1.70 (3H, d, J = 6.6 Hz) in M6 and δH 1.62 (3H, d, J = 6.0 Hz) in M7 
indicated the existence of a rhamnose moiety. Compared with the NMR data of magnoloside F 
[41], allose and glucose moieties were suggested in both M6 and M7. Additionally, M6 
contained a syringoyl group which was indicated by the signals of two equivalent methoxys δH 
3.56 (6H, s), two equivalent aromatic protons δH 7.50 (2H, s) and one carbonyl carbon δC 166.3. 
The deshielded shift of C-6' (δC 66.2, allose) and C-4''' (δC 84.8, rhamnose) indicated the linkages 
between syringoyl and C-6', glucose and C-4''', respectively, which were confirmed by the 
correlations of H-6' (δH 5.31, 4.91, allose)/C-7'''' (δC 166.3, syringoyl), H-1'' (δH 5.31, 
glucose)/C-4''' (δC 84.8, rhamnose), H-1''' (δH. 6.07, rhamnose)/C-4'''' (δC 139.4, syringoyl), and 







Fig. 1.2 Key HMBC and NOESY correlations of M7 and M9 
 
Compared with the NMR data of M6, an additional set of ABX-type aromatic signals and only 
one methoxy were suggested in M7, which indicated the existence of a vanilloyl group. The 
methoxy was assigned to C-3'''' (δC 150.2) aided by the correlation between the protons of 
methoxy (δH 3.63) and H-2'''' (δH 7.80, d, 1.8 Hz) in nuclear overhauser effect Spectrometry 
(NOESY) (Fig. 1.2). Thus compound M7 was assigned as 2-(3,4-dihydroxyphenyl)-ethyl 
1-O-{6-O-[4-O-β-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl]-vanilloyl}-β-D-allopyranoside
. 
Magnolosides V (M8) and W (M9) were obtained as white amorphous powders, and had the 
molecular formulae of C36H50O21 and C35H48O20 based on HRESIMS m/z 817.2749 [M-H]
- 
(calcd for C36H49O21, 817.2766) and 787.2666 [M-H]
- 
(calcd for C35H47O20, 787.2661), 
respectively. The 
1
H NMR of M8 (Table 1.4) exhibited AA'BB'-type aromatic protons at δH 7.31 
(2H, d, J = 9.0 Hz), 7.27 (2H, d, J = 9.0 Hz), and 1,2-dihydroxypropyl signals at δH 3.11 (1H, dd, 
J = 13.2, 5.4 Hz), 2.97 (1H, dd, J = 13.2, 7.8 Hz), 4.28 (1H, overlap), 4.01 (1H, dd, J = 10.8, 4.2 
Hz), and 3.96 (1H, dd, J = 10.8, 6.0 Hz), which suggested that the aglycone was a 
4-(1,2-dihydroxypropyl)-phenol [39].
 
Comparison of the NMR data of M8 with those of M6 
indicated the existence of syringoyl, allose, glucose and rhamnose moieties in M8. The 
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connectivities of H-1''' (δH 5.30, glucose)/C-4'' (δC 84.6, rhamnose), H-1'' (δH 6.11, 
rhamnose)/C-4'''' (δC 139.3, syringoyl), H-6' (δH 5.35, 4.93, allose)/C-7'''' (δC 166.0, syringoyl), 
H-1' (δH 6.01, allose)/C-1 (δC 157.0, aglycone) were established by an HMBC experiment. 
Accordingly, M8 was confined as 4-(1,2-dihydroxypropyl)-phenyl 
1-O-{6-O-[4-O-β-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl]-syringoyl}-β-D-allopyranoside. 
The difference between M9 and M8 is that the syringoyl moiety in M8 was replaced by a 
vanilloyl in M9, which was supported by the signals of a set of ABX-type aromatic protons and 
a methoxy. The methoxy group was assigned to C-3'''' (δC 150.4), this being aided by the 
correlation between the protons of methoxy group (δH 3.67) and H-2'''' (δH 7.80, d, J = 1.8 Hz) in 
NOESY (Fig. 1.2). Thus, M9 was assigned as 4-(1,2-dihydroxypropyl)-phenyl 
1-O-{6-O-[4-O-β-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl]-vanilloyl}-β-D-allopyranoside
. 
Magnolosides X (M10) and Z (M11) were isolated as pale yellow amorphous powders, and 
their molecular formulae were assigned to be C30H40O16 and C29H38O15 based on the HRESIMS 
m/z 701.2317 [M+HCOO]
- 
(calcd for C31H41O18, 701.2293) and 671.2215 [M+HCOO]
- 
(calcd for 
C30H39O17, 671.2187), respectively. The 
1
H NMR spectrum of M10 (Table 1.4) exhibited signals 
for AA'BB'-type aromatic protons, a 1, 2-dihydroxypropyl moiety, a syringoyl moiety and two 
anomeric proton resonances at δH 5.30 (1H, d, J = 7.8 Hz) and 5.40 (1H, s). The NMR data of 
M10 were similar to those of M8, except for the absence of a terminal glucose in M10. The 
HMBC spectrum established correlations of H-1' (δH 5.30, allose)/C-1 (δC 157.6, aglycone) and 
H-1'' (δH 5.40, rhamnose)/C-4''' (δC 140.5, syringoyl). The deshielded shift of C-6' (δC 67.6, allose) 
showed a linkage between syringoyl and C-6'. Thus, M10 was assigned as 4-(1, 
2-dihydroxypropyl)-phenyl 
1-O-{6-O-[4-O-α-L-rhamnopyranosyl]-syringoyl}-β-D-allopyranoside. The difference between 
M11 and M10 was that the syringoyl moiety in M10 was replaced by a vanilloyl in M11, which 
was supported by the signals of a set of ABX-type aromatic protons and a methoxy. The 
methoxy group was assigned to C-3'''' (δC 151.8) aided by the correlation between protons of 





In conclusion, ten PhGs (M1-7, M12-14) and seven phenolic glycosides (M8-11, M15-17) 
were isolated from the water-soluble portion of the 70% (v/v) EtOH aqueous extract of the stem 




C NMR and DEPT), 
2D (HSQC, HMBC, and NOESY) NMR spectroscopy, mass spectrometry (ESIMS, HRESIMS), 
GC and chemical hydrolysis methods and in comparison with literature data. The large number 
of glycosides isolated and identified further fully indicated the ubiquity of glycosides in MO. 





Chapter 2  Biological Activity of Phenylethanoid Glycoside from Magnoliae Officinalis 
Cortex 
 
Natural products are a consistent source for drug discoveries [43, 44]. Evaluation of 
bioactivity is indispensable to screen potential drug candidates. Diabetes and cancers are now very 
common worldwide with a high prevalence and have strongly influenced patient’s quality of life, 
work performance and family relationships, as well as being highly expensive for healthcare. The 
bark of MO is usually used for the treatment of abdominal distention and pain, dyspepsia, and 
asthmatic cough, but modern pharmacology studies showed that the extract of MO also had 
significant anti-tumor activities. The aqueous extract of MO showed anti-tumor activity on urinary 
bladder cancer in vitro and in vivo, which was associated with the upregulation of proapoptotic 
molecules Bax, cytochrome c and caspase 3 [45], and the MeOH extract exhibited remarkable 
inhibitory effects on mouse skin tumor promotion in vivo [46]. In addition, the constituent of 
honokiol, a main compound isolated from MO, had potential cytotoxic activities against human 
gastric carcinoma, human colorectal carcinoma, human pancreatic cancer cells, human thyroid 
cancer cells, T98G human glioblastoma cells, U87MG human glioblastoma cells, MGC-803 cell, 
malignant glioma and multiple myeloma cells [47-52], and another primary compound magnolol 
was demonstrated to have potential cytotoxic activities towards mammary cancer cells, lung 
cancer cells and human prostate cancer cells [53-55]. Besides, PhGs were also reported to own 
obvious cytotoxic activities, for instance, salidroside could inhibit the proliferation of MCF-7 
cells and promoted the apoptosis of MCF-7 cells in a dose-dependent manner by increasing the 
activity of caspase, up-regulating the Bax expression, and down-regulating the Bcl-2 expression 
[56], and acteoside was reported to have the potential to be a potent anticancer agent in the 
treatment of fibrosarcoma metastasis [57].  
Besides the anti-tumor activity, PhGs were also investigated to have α-glucosidase 
inhibitory such as stewartiiside and 2'-rhamnoechinacoside isolated from tepal of M. salicifolia 
and Phlomis stewartii, respectively [58]. Diabetes Mellitus are characterized by postprandial 
hyperglycemia or hyperinsulinemia. Alpha-glucosidase is an enzyme that catalyzes the final step 
in the digestive process of carbohydrate [59], and α-glucosidase inhibitors such as acarbose, 
miglitol and voglibose were known to reduce postprandial hyperglycemia primarily by 
interfering with the carbohydrate-digesting enzymes and delaying glucose absorption [60]. 
However, the inhibitors have various side-effects such as liver toxicity and adverse 
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gastrointestinal symptoms, thereby raising the risk factors of heart disease [61]. Therefore, safer 
natural α-glucosidase inhibitors are needed and many compounds have been reported from plant 
sources [62-64]. Several methods concerning α-glucosidase inhibitory activity of natural 
products against maltose, sucrose and p-nitrophenyl-α-D-glucopyranoside (PNPG) were reported. 
However, the process using maltose and sucrose as substrates was a little tedious, of which the 
reaction was stopped by filtration in the column or the reaction mixture need to be passed 
through a short column [65, 66]. Meanwhile, the two measurement methods need to determine 
the glucose released, in which the sucrose or some phenolic compounds could interfere with the 
glucose measurement [65, 66]. What’s more, the natural products were generally light-colored or 
colored, it was another interference with the measurement. Thus, in the current study, the method 
using PNPG as substrate, of which the reaction was simply to be stopped and the liberated 
p-nitrophenyl was easily to be determined without interference, was used with minor 
modification [63]. 
Considering the modern pharmacological activities of MO or its constituents as well as 
PhGs isolated from other medicinal plants, in this chapter, the α-glucosidase inhibitory effect and 
cytotoxicity of PhGs isolated from MO were dealt with to be determined. 
 
2.1 α-Glucosidase Inhibitory Effects  
 
2.1.1 α-Glucosidase Inhibitory Activity Assay 
α-Glucosidase (from Saccharomyces cerevisiae; Sigma-Aldrich, St. Louis, MO, USA) 
inhibitory activities were determined by using PNPG as a substrate and acarbose as a positive 
control compound, according to the reported method [63] with minor modifications.
 
Enzyme 
solution [50 μL, 0.26 U/mL in 0.05 M potassium phosphate buffer (pH 6.8)] and test compound 
[50 μL, 1 mM in 0.05 M potassium phosphate buffer (pH 6.8)] were mixed and pre-incubated in 
96-well plates for 10 min at 37°C prior to initiation of the reaction by adding the substrate. After 
pre-incubation, PNPG solution, 100 μL, 5.0 mM in 0.05 M potassium phosphate buffer, pH 6.8, 
was added and then incubated together at 37°C for 20 min. After incubation, 0.2 M Na2CO3 (100 
μL, in 0.05 M potassium phosphate buffer) was added to each well to stop the reaction. The 
amount of p-nitrophenol (PNP) released was quantified by using a Varioskan Flash Multimode 
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Reader (Thermo scientific, Finland) at 405 nm. The percent inhibition of α-glucosidase was 
calculated as inhibition rate (%) = [1 - (Asample - As-blank) / (Acontrol - Ablank)] × 100. Asample stands 
for the absorbance of enzyme, sample and substrate, As-blank stands for the absorbance of sample 
and substrate, Acontrol stands for the absorbance of enzyme and substrate, and Ablank stands for the 
absorbance of substrate. Samples possessed strong activity, which had an inhibitory rate more 
than 50% at 1 mM. The inhibitory activities of samples were further evaluated to obtain their 
IC50 (half maximal inhibitory concentration) values. 
 
2.1.2 α-Glucosidase Inhibitory Effects of Phenylethanoid Glycosides 
IC50 of the isolated compounds were evaluated for their α-glucosidase inhibitory effects, and 
acarbose was used as a positive control [62]. Compounds M1 and M3 showed strong inhibition 
(IC50 was 0.13 and 0.27 mM, respectively), whereas compounds M4 and M10-14 exhibited 
moderate inhibition (IC50 in the range 0.62-0.94 mM) compared to acarbose (IC50 1.09 mM) 
(Table 2.1). Conversely, the phenolic glycosides 8 exhibited inhibitory rate less than 50 % at a 
concentration of 1.0 mM. This result suggested that PhGs have strong inhibitory activities, and 
the contribution of coumaroyl, feruloyl, and caffeoyl groups to the bioactivity was decreased in 
sequence. 
 
Table 2.1 Inhibitory effects of isolated compounds against α-glucosidase 
a
. 
Compounds  IC50 (mM) Compounds IC50 (mM) 
M1 0.13 + 0.01 M11 0.94 + 0.02 
M3 0.27 + 0.01 M12 0.75 + 0.17 
M4 0.68 + 0.01 M13 0.62 + 0.02 
M8 N
b
 M14 0.69 + 0.10 
M10 0.94 + 0.02 Acarbose 1.09 + 0.04 
a
 Each value represents the mean ± SD (n = 3). 
b




2.2.1 Cytotoxicity Assay 
The cytotoxic activity was determined against stomach cancer (MGC-803), liver cancer 
(HepG2), prostate cancer (PC3), PC12 cell strain, lung cancer (A549) and normal kidney cells 
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(Vero) obtained from China center for type culture collection (CCTCC). Measurements were 
based on a previously reported method [71]. Cells were seeded in 96-well plates at a cell density 
of 2~5×10
3
 per well, 24 h later, treated with various concentrations of compounds. After 72 h of 
incubation, MTT was added to each well. Then the plates were incubated for 4 h, and the cells 
were lysed with 150 μL DMSO after removal of the supernatant liquid. Cell viability was 
measured by observing absorbance at 570 nm on a Varioskan Flash Multimode Reader. The cell 
viability rate (%) = (Asample-Ablank)/(Acontrol-Ablank) × %, Asample stands for the absorbance of well 
added medium, cells, sample and MTT, Ablank stands for the absorbance of well added medium 
and MTT, and Acontrol stands for the absorbance of well added medium, cells and MTT. 
 
2.2.2 Cytotoxicity of Phenylethanoid Glycosides 
According to the result of a network pharmacological study, the isolated compounds were 
predicted to have cytotoxic activities. In addition, several PhGs were reported to possess 
cytotoxic activity [67-70]. Accordingly, the cytotoxicity of the isolated compounds against 
MGC-803, HepG2, PC3, PC12, A549 and Vero were evaluated using an MTT assay [71]. Being 
a widely used broad-spectrum anticancer drug, fluorouracil (5-FU) was chosen as a positive 
control [72]. Compounds M2-4, M6, M7 and M12-14 showed moderate cytotoxicity against 
MGC-803 and HepG2, while compounds M10, M11, M15 and M17 showed no cytotoxicity 
against MGC-803 and HepG2. Among the PhGs, compounds M12 and M14 exhibited preferable 
cytotoxic activity against MGC-803 with IC50 of 14.60 and 17.16 μM, respectively. Additionally, 
they also exhibited certain cytotoxic activities against HepG2 with IC50 of 29.53 and 31.26 μM, 
respectively, and had no cytotoxicity on Vero. Except for compounds M12 and M14, all 
evaluated compounds showed no cytotoxicity against PC3, PC12 and A549 (Table 2.2). 
In conclusion, most evaluated PhGs showed good α-glucosidase inhibitory effects with IC50 
values ranging between 0.13 and 0.75 mM and moderate cytotoxicity against human cancer cell 
lines MGC-803 and HepG2 with IC50 values of 14.60~54.00 μM and 29.53~63.82 μM, 






Table 2.2 Cytotoxicity of isolated compounds against MGC-803, HepG2, PC3, A549, PC12, and 
Vero. 
Compounds  MGC-803 HepG2 PC3 A549 PC12 Vero 
IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 
M2 49.77±5.12 58.38±3.33 >100 >100 >100 >100 
M3 38.40±3.23 48.82±2.20 >100 >100 >100 >100 
M4 26.51±3.11 32.18±2.76 >100 >100 >100 >100 
M6 45.24±3.45 54.88±4.32 >100 >100 >100 >100 
M7 54.00±4.23 63.82±8.89 >100 >100 >100 >100 
M10 >100 >100 >100 >100 >100 >100 
M11 >100 >100 >100 >100 >100 >100 
M12 17.16±2.56 31.26±2.18 >100 75.11±5.90 99.79±6.95 >100 
M13 24.79±3.45 32.62±4.32 >100 >100 >100 >100 
M14 14.60±2.33 29.53±3.29 98.43±6.21 47.12±1.89 88.14±7.75 >100 
M15 >100 >100 >100 >100 >100 >100 
M17 >100 >100 >100 >100 >100 >100 





















Chapter 3  Quantitative Analysis of Phenylethanoid Glycosides from Magnoliae 
Officinalis Cortex by A Novel 2LC-ECD Method 
 
China is vast in territory with diversified landforms and mountain ranges, and hence diverse 
geographical and climatic conditions. TCMs are harvested from various parts of China and the 
locales play an important role in the quality control of TCMs, the concept of Daodi medicinal 
material [73-76], which associates the authenticity and quality with specific geographic regions 
and production practices, e.g. “huai di huang”, “chuan po”, etc. is of importance to help provide 
suitable medical and pharmaceutical care in the field of TCMs. 
MOCs were originated from MO and MOB. The two medicinal plants were distributed from 
Sichuan of the west to Zhejiang of the east and from Shaanxi in the north to Guangxi in the south 
in China. In the case of MOC, samples of MOC produced in Hubei and Sichuan were 
traditionally regarded as Daodi medicinal material according to the textual research, which were 
called Chuan po. Other samples from other habitats have not been regarded as Daodi medicinal 
material. As the MOC samples derived from the districts of Zhejiang and Fujian were prolific 
and had a wide circulation, they were generally referred to as Wen po. Considering the limited 
resources of Daodi medicinal material, Daodi medicinal material and material from other 
habitats were both circulated in markets and used in clinic [77]. To ensure the safety and efficacy 
of the TCMs used in clinics, it is important to ensure the quality of Daodi medicinal materials 
and others. Because Wen po has a large production and wide circulation, it was taken as a case 
study to exemplify other MOC samples from other habitats. In the first and second chapters, 
PhGs were found to exist largely in MO and had some outstanding bioactivity, such as 
α-glucosidase inhibitory effects and cytotoxic activities. In this chapter, PhGs were applied as 
the targeted compounds to be quantified and then search the chemical difference between Chuan 
po and Wen po. 
LC-ECD is a useful method for the component analysis of TCM due to its high sensitivity and 
selectivity for redox compounds such as flavonoid glycosides, caffeoylquinic acids and PhGs 
[18]. One of the major aims of the present study is to provide a novel method to discriminate 
between MOC samples of Chuan po and Wen po based on the quantitative profiles of seven 
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PhGs, i.e., magnolosides A, B, D, F, H, L, and M as shown in Fig. 3.1. To address the above 
purpose, a multi-channel LC-ECD was utilized to determine PhGs in MOC by the following two 
means: (1) Phenolic hydroxy groups in substances such as PhGs have electrochemical activity 
[16, 17], so that it is expected that sensitive detection of PhGs in MOC can be performed by 
ECD. And the sensitivity of ECD is high enough to detect the low concentrations of 
magnolosides D, F, H, L, and M. (2) Gradient elution is generally an inadequate selection in 
ECD, because the changing mobile phase composition by gradient elution usually causes 
chromatographic baseline drift and remarkably reduces the sensitivity in ECD. Because it is 
inevitable to take a long time to elute all analytes from a column in a single isocratic elution, 
multi LC-ECD is useful to shorten the measurement time and to keep sensitivity when the 
hydrophilic properties of analytes are remarkably different [18, 19]. By the established 
2LC-ECD method, seven PhGs were simultaneously determined with high sensitivity. 
Meanwhile, pattern recognition analysis was performed for the differentiation of MOC samples 
between Chuan po and Wen po. What’s more, discriminant variables were screened by their 





Fig. 3.1 Structures of PhGs as analytes. 
 
3.1 Development of 2LC-ECD for Determining Phenylethanoid Glycosides 
 
3.1.1 Chemicals and Reagents 
The reference compounds of magnolosides A, B, D, F, H, L, and M shown in Fig. 3.1 were 
isolated from the stem bark of MO [41]. The purity of each reference compound was determined 
to be more than 95% by normalization of the peak areas detected by LC-ECD. Ethyl gallate 
(>98%) and hyperoside (>98%) shown in Fig. 3.2 were purchased from Tokyo Chemical 
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Industry Co., Ltd. (Tokyo, Japan) and Funakoshi Co., Ltd. (Tokyo, Japan), respectively. Water 
for HPLC analysis was distilled and purified with a NANO Pure II filtering system (Barnstead 
Co., Ltd., Boston, MA, USA). Acetonitrile (MeCN, HPLC grade) and formic acid (FA, LC/MS 
grade) were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
 
      
Ethyl gallate                                Hyperoside 
Fig. 3.2 Structure of internal standards. (Ethyl gallate and hyperoside were used as internal standards for 
determining PhGs in channels 1 and 2 of the 2LC-ECD, respectively.) 
 
3.1.2 Arrangement of Detection Channels in 2LC-ECD 
PhGs were primarily separated by an isocratic LC-ECD system using an MeCN-H2O-FA 
(12:88:0.6, v/v/v) mobile phase flowed at 45 μL/min and a C30 column (Develosil C30-UG-3 
(1.0 × 250 mm, 3 μm)) maintained at 35°C. In our preliminary experiments, several types of 
columns were tested to roughly know the ability of a column for the suitable separation of the 
PhGs: InertSustain C18 (1.0 × 250 mm, 3 μm, GL Sciences, Tokyo, Japan), Capcell pak C18 
UG120 (1.0 × 150 mm, 3 μm, Shiseido, Tokyo), MonoBis ODS (1.0 × 150 mm, GL Sciences), 
Develosil C30-XG-3 (1.0 × 250 mm, Nomura Chemical), Develosil C30-UG-3 (1.0 × 250 mm, 
Nomura Chemical). The detailed information for these columns was shown in Table 3.1. Better 
resolutions for magnolosides A, B, F, H, and L were obtained (Rs > 1.3) by the usage of 
Develosil C30-XG-3 (1.0 × 250 mm), and thus it was selected as the optimal column for the 
isocratic LC-ECD. By the isocratic LC-ECD, magnolosides A, B, F, H, and L were detected 
within 60 min after sample injection, meanwhile magnolosides D and M were detected at 469.1 
and 174.0 min, respectively. Thus, a measurement time of about 480 min was required to elute 
all of the PhGs by the present isocratic LC-ECD system. Although gradient elution is of great use 
to shorten measurement time, the stable electrochemical double layer on the working electrode 
surface is not maintained by changing the mobile phase composition, which leads to baseline 
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noise drift and sensitivity decline compared with isocratic LC-ECD. Indeed, in the case of the 
isoflavone determination, quantitation limits of daidzin by LC-ECD with gradient [78] and 
isocratic [19] elution were 52000 pg and 2.5 pg, respectively. Thus, two different isocratic 
elutions were flowed on two different detection channels, respectively, to keep a stable 
electrochemical double layer on the working electrode surface. Although all of the analytes 
belong to the same type compound of PhGs, they were still separated into two groups to design a 
multi LC-ECD using an SV. Magnolosides B, F, and H owning three sugars in the structures 
were in group I, while magnolosides A, D, L, and M owning two sugars in the structures were in 
group II. The hydrophilicities of group I were higher than that of group II. The structures of 
magnolosides A, D, L, and M are almost the same except that the linkage sites of the caffeoyl 
moiety are different, however, magnolosides A and L were eluted with group I. The caffeoyl 
moiety linked to 3-C of the core sugar contributes to the hydrophilicity of the PhGs compared 
with those of linked to 4/6-C of the core sugar, therefore the elution times of magnolosides A and 
L were faster than that of magnolosides D and M in the above isocratic LC-ECD. In order to 
obtain an optimal chromatographic system to analyze PhGs in the MOC sample, several different 
channel connection designs of an LC-ECD system [18, 19] were investigated. However, the 
resolution of some PhGs worsened in both of the two previous systems due to their close 
hydrophilicity. The present 2LC-ECD system shown in Fig. 3.3 was finally adopted in this study. 
Based on the findings concerned with the results of the above isocratic LC-ECD, the detection of 
magnolosides A, B, F, H, and L and IS1 was performed by D1 in CN1. After the rotation of SV at 




Table 3.1 Detailed information for the tested columns 
Particle   packed 
column 







InertSustain C18 Spherical silica gel Octadecyl 
group 
3 μm 10 nm 14% 350 m
2
/g 0.85 mL/g Complete 
Capcell pak C18 
UG120 
Spherical silica gel Octadecyl 
group 
3 μm 12 nm 15% 300 m
2
/g 1.00 mL/g Complete 
Develosil C30-XG-3 Spherical silica gel Triacontyl 
group 
3 μm 14 nm 19.5% 300 m
2
/g 1.10 mL/g Complete 
Develosil C30-UG-3 Spherical silica gel Triacontyl 
group 
3 μm 14 nm 18% 300 m
2
/g 1.05 mL/g Complete 







Size Total porosity Size Total porosity 




1.4 μm 65% 11 nm 10% 19% 360 m
2




Fig. 3.3 Schematic illustration of the proposed 2LC-ECD system. The initial position is shown in (A); flow 
way on SV changed at 60 min after sample injection is shown in (B). (MP1-2, mobile phase; DG, vacuum 
degasser; P1-2, pumps; Inj., sample injector; SV, switching valve; D1-2, electrochemical detector; R, recorder; W, 
waste.) 
 
3.1.3 Optimization of 2LC-ECD Conditions 
The chromatographic conditions in CN2 such as the mobile phase and flow rate were 
optimized to shorten the elution time of magnolosides D and M in 2LC-ECD. An examination 
was made to test how the ratio of MeCN and H2O in the MP2 influenced the separation of 
magnolosides D and M. The elution time for magnolosides D and M was shortened with an 
increase in the content of MeCN in MP2. Moreover, another examination was made concerning 
the concentration of FA, i.e., the pH values in the MP2 influenced the peak shape and redox 
reaction occurring in the electrochemical cell [18]. MeCN-H2O-FA (20:80:0.6, v/v/v) was 
chosen as an optimal MP2 for determining magnolosides D and M with an adequate resolution 
and within a short time, and flow rate was selected as 35 μL/min. The longer column was used to 
obtain a well separation effect. Based on the appropriate resolution of each analyte in each 
channel, the analytical time of the sample was shortened from 480 min to 85 min by increasing 
the ratio of organic phase, adjusting the flow rates, increasing the oven temperature, and so on. 
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Hydrodynamic voltammograms of PhGs were obtained to select the optimal applied potential 
in D1 and D2. As shown in Fig. 3.4, PhGs were oxidized at a potential more positive than +0.4 V 
vs. Ag/AgCl, and their oxidation waves were observed at +0.6-+0.8 V vs. Ag/AgCl. The peak 
current heights of PhGs were raised with the increase of the applied potential. When the potential 
was more than +0.8 V vs. Ag/AgCl, the peak heights were decreased. Based on the 
signal-to-noise ratio (S/N) of peak heights for PhGs as criteria, the applied potentials in D1 and 
D2 were set at +0.8 V vs. Ag/AgCl. Using isocratic LC-ECD without an SV, the elution of PhGs 
required a 480 min analysis, while through alternately rotating SV at 60 min to change the 
elution flow way in 2LC-ECD, all of the PhGs studied were determined within 85 min. 
 
 
Fig. 3.4 Hydrodynamic voltammogram of PhGs in both two channels. (Each PhG of 1 μM was injected into 
the 2LC-ECD; Optimized HPLC conditions were used except for the applied potentials) 
 
3.1.4 Method Validation for 2LC-ECD System 
 
3.1.4.1. Linearity and linear range 
The linearity of the present 2LC-ECD method was established by an internal standard method. 
Considering the factors of stability, dissolubility, the response value of peak current, and the 
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resolution, the compounds of ethyl gallate (IS1) and hyperoside (IS2) were selected as internal 
standards (IS) in CN1 and CN2, respectively. A series of mixed reference compounds solutions of 
25 concentration levels (0.002, 0.004, 0.006, 0.008, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, 
0.8, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 14.0, 16.0, 18.0, 20.0 μM) with constant concentrations of 
two ISs (3.63 and 1.07 μM for IS1 and IS2, respectively) were freshly prepared, and were used to 
determine the linear range of the analytes. Linearity was assessed by means of linear regression 
with respect to the concentrations and peak height ratios of the analytes to IS. 
The chromatographic peak height ratios of PhGs to each IS were found to be linearly related 
to the PhGs concentrations, and the linear ranges for each PhG and the correlation coefficient (r) 
of these calibration curves are shown in Table 3.2.  
 















Determined in CN1 and calibrated with IS1 
A 0.01 - 12.0 y = 0.3038x + 0.0088 0.999 2.7 10 
B 0.01 - 8.0 y = 0.2363x + 0.0007 0.999 4.9 10 
F 0.02 - 12.0 y = 0.1797x + 0.0057 0.999 6.2 20 
H 0.02 - 16.0 y = 0.2098x - 0.0033 0.999 7.4 20 
L 0.02 - 12.0 y = 0.1674x + 0.0044 0.999 7.7 20 
Determined in CN2 and calibrated with IS2 
M 0.002 - 4.0 y = 1.6412x + 0.0302 0.999 0.6 2 
D 0.002 - 6.0 y = 1.2212x + 0.04 0.999 0.8 2 
a
 A, B, D, F, H, L and M mean magnolosides A, B, D, F, H, L, and M.
 
b
 x, concentration of reference compounds solution (μM); y, peak height ratio of magnoloside to IS.  
c
 Number of data (n) to obtain the correlation coefficient (r): magnoloside A, 17; B, 15; D, 18; F, 16; H, 18; L, 
16; M, 17.  
 
3.1.4.2. Limits of quantification and detection 
The limit of quantification (LOQ) determined as the amounts of the S/N was 10, and the limit 
of detection (LOD) were determined by calculation of the S/N of 3. The LODs (S/N = 3) of 
magnolosides A, B, D, F, H, L, and M were 2.7, 4.9, 0.8, 6.2, 7.4, 7.7 and 0.6 nM with LOQs 
(S/N = 10) of 10, 10, 2, 20, 20, 20, and 2 nM, respectively, as shown in Table 3.2. To date, 
although analysis for the identification of PhGs in TCM and the evaluation of biological 
activities of PhGs has been performed [9, 41], there has been only one report that is concerned 
with the determination of the chemical composition of magnolosides A and B in MOC using 
liquid chromatography with diode array detection (LC-DAD) [79]. The LODs of magnolosides 
A and B by LC-DAD were 96.0 and 99.2 ng/injection, respectively [79], while those by the 
present 2LC-ECD were 8.4 and 19.3 pg/injection, respectively. Thus, the present 2LC-ECD is 
ten thousand times more sensitive than the existing LC-DAD for determining PhGs. To the best 
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of our knowledge, the present study is the first time to simultaneously determine magnolosides A, 
B, D, F, H, L, and M using a chromatographic technique. 
 
3.1.4.3. Precision and stability  
The mixed reference compounds solution of 0.8 μM was determined six times with a relative 
standard deviation (RSD) of less than 2.8% as shown in Table 3.3. 
 







 2 3 4 5 6 Mean RSD 
A 0.235 0.230 0.224 0.222 0.224 0.225 0.227 2.2% 
B 0.194 0.194 0.190 0.190 0.187 0.186 0.190 1.8% 
D 1.011 0.995 0.960 0.950 0.950 0.950 0.969 2.8% 
F 0.139 0.136 0.140 0.139 0.140 0.132 0.138 2.3% 
H 0.154 0.159 0.159 0.157 0.161 0.161 0.159 1.7% 
L 0.137 0.134 0.131 0.130 0.131 0.130 0.132 2.1% 
M 1.357 1.351 1.300 1.296 1.300 1.305 1.318 2.1% 
a
 Each magnoloside of 0.8 μM was injected into the 2LC-ECD. 
b
 A, B, D, F, H, L and M mean magnolosides A, B, D, F, H, L, and M.
 
c
 Peak height ratio of the analyte to IS. 
 
To examine the stability of PhGs in test solutions, a test solution was stocked below 10°C 
without avoiding light for 0, 6, 12, 24, 36, and 48 h after sample preparation, and then their 
chromatograms were immediately measured. The RSD values for chromatographic peak height 
ratio of each PhG to the IS within 48 h ranged from 2.7 to 5.0% as shown in Table 3.4. 
Considering these results, it was feasible to analyze samples within two days. 
 
Table 3.4 Stability evaluation of PhGs in a sample solution of MOC 
a
 
Storage Peak height ratio of each magnoloside to the IS 
time A B D F H L M 
0 h 0.504 0.150 0.047 0.067 0.079 0.065 0.447 
6 h 0.491 0.149 0.050 0.072 0.079 0.06 0.445 
12 h 0.482 0.150 0.053 0.067 0.077 0.058 0.468 
24 h 0.469 0.143 0.050 0.067 0.082 0.059 0.450 
36 h 0.45 0.141 0.049 0.063 0.082 0.059 0.432 
48 h 0.454 0.145 0.047 0.063 0.084 0.059 0.463 
Mean 0.475 0.146 0.049 0.067 0.081 0.060 0.451 
RSD (%) 4.5 2.7 4.6 5.0 3.2 4.2 2.9 
a
 Samples from Hubei (# ES4) were analyzed in this experiment as an example of MOC. 
 
3.1.4.4. Repeatability and accuracy 
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The repeatability of the present method was obtained by analyzing six samples of the same 
batch of MOC sample using the same preparation procedure. The RSDs of the contents of each 
PhG were below 5.1% (n = 6) shown in Table 3.5. 
 





 2 3 4 5 6 Mean RSD 
A 20.63  19.50  20.03  20.73  21.10  20.20  20.37  2.8% 
B 37.35  36.04  36.53  38.29  38.20  37.15  37.26  2.4% 
D 0.11  0.11  0.11  0.11  0.12  0.11  0.12  4.1% 
F 12.69  11.96  12.00  12.69  12.23  12.65  12.37  2.8% 
H 5.26  5.13  5.31  5.23  5.43  5.21  5.26  1.9% 
L 2.46  2.41  2.30  2.60  2.60  2.60  2.50  5.1% 
M 2.48  2.35  2.52  2.40  2.46  2.47  2.45  2.6% 
a




unit is mg/g. 
 
To evaluate accuracy, the recovery test was carried out using a reference compound spiked 
method. Three levels of reference compounds solution containing the seven analytes were spiked 
into the sample solution, such that the amount of each analyte in the reference compounds 
solution was almost equal to or 50% or 150% of that in the sample solution. The sample was 
then extracted according to the sample preparation procedure. 
 














































































































The recoveries of PhGs for the spiked sample solutions were between 89.1% and 109.5% with 
an RSD (n = 3) of less than 5.7% shown in Table 3.6. Using reported conditions of LC-DAD for 
determining magnolosides A and B [79], the contents of magnolosides A and B in MO were also 
determined by HPLC with ultraviolet detection (HPLC-UV) to compare them with the results by 
2LC-ECD as shown in Table 3.5. The contents of magnolosides A and B in MO (# ES3) by 
HPLC-UV were 20.31 and 37.35 mg/g with RSDs (n = 6) of 4.3% and 4.9%, respectively, 
showing that the results by HPLC-UV were almost consistent with those by 2LC-ECD. These 
results demonstrate that the present 2LC-ECD method was characterized by satisfied precision, 
higher repeatability, and accurate measurements of the seven PhGs. The specificity of ECD to 
phenolic compounds including PhGs is better than UV detection which is a common detection 
method in conventional HPLC. In the current study, seven PhGs were determined by 2LC-ECD 
with a simple sample preparation step. Although 85 min measurement time was required for the 
2LC-ECD to determine the seven PhGs, the 2LC-ECD was able to avoid complicated sample 
preparation using solid and/or liquid phase extractions, troublesome and cumbersome column 
and working electrode conditionings, and a loss of sensitivity using gradient elution in the 
quantitative analysis for MOC samples. 
 
3.2 Geographical Discrimination of Magnoliae Officinalis Cortex by 2LC-ECD and 
Multivariable Analysis 
 
3.2.1 Plant Materials and Sample Preparation 
Chuan po (36 batches) and Wen po (18 batches), as MOC samples shown in Table 3.7, were 
directly harvested by the authors during field work in nine nature habitats (MO from Enshi (ES), 
Jianshi (JS), Xuan’en (XE), Badong (BD), Hefeng (HF) and Dujiangyan (DJY); MOB or MO 
from Qingyuan (QY), Minhou (MH) and Wuyishan (WYS) of China. All the voucher samples 
were authenticated by the authors and deposited in the Institute of Chinese Materia Medica, 
China Academy of Chinese Medical Sciences (Beijing, China). 
The MOC samples were powdered to a homogeneous size and sieved through a No. 50 mesh. 
The accurately weighed dried powders (0.1 g) were dissolved in 1.5 mL of 70% (v/v) MeOH 
aqueous and ultrasonically extracted at 35°C for 30 min (110 W, 40 kHz) to prepare the sample 
solutions. After being centrifuged at 20630 g for 5 min, the 5 μL of supernatants were spiked 
with 25 μL of mixed solutions including IS1 (72 μg/mL) and IS2 (50 μg/mL). Then, the solution 
was diluted with an MeCN-H2O-FA mixture (12:88:0.6, v/v/v) to 5.0 mL. This solution was 
filtered through a 0.2 μm membrane filter to prepare the test solution for the 2LC-ECD analysis. 
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3.2.2 Determination of Phenylethanoid Glycosides in Magnoliae Officinalis Cortex by 
2LC-ECD 
A typical chromatogram of mixed reference compounds is shown in Fig. 3.5A. The 
chromatographic peaks of magnolosides B, H, A, L, and F and IS1 appear at 24.5, 29.2, 42.5, 
47.5, 53.3, and 35.0 min in CN1, respectively, and the value of resolution (Rs) between 
magnolosides A and L was 1.38. Meanwhile the chromatographic peaks of magnolosides M and 
D and IS2 appeared at 73.3, 84.2, and 75.8 min in CN2, respectively, and the values of Rs 
between magnoloside M and its close peak were more than 1.50. The theoretical plate numbers 
(N) for the peaks of magnolosides B, H, A, L, F, M, and D were 899, 1268, 1736, 2123, 1908, 
28193, and 18518, respectively. The tailing factors of all peaks for PhGs were in the range of 
0.95-1.05, so the peak height quantification made sense. 
Since the analytical method was established and validated, these seven PhGs in the 72 batches 




Fig. 3.5 Typical chromatograms obtained from (A) mixed reference compound solution and (B) MOC sample 
solution. (Chromatograms in blue and pink lines were obtained from the first (CN1) and second channels (CN2) 
in the 2LC-ECD, respectively; Chromatographic peaks of PhGs were marked in Figure; IS1 and IS2 mean 











Table 3.7 List of magnoliae officinalis cortex (MOC) samples 
Authentication Habitat Collection date Sample # 
Chuan po 
a
 Enshi, Hubei 05, 2017 ES1 
 Enshi, Hubei 05, 2017 ES2 
 Enshi, Hubei 05, 2017 ES3 
 Enshi, Hubei 05, 2017 ES4 
 Enshi, Hubei 05, 2017 ES5 
 Enshi, Hubei 05, 2017 ES6 
 Jianshi, Hubei 05, 2017 JS1 
 Jianshi, Hubei 05, 2017 JS2 
 Jianshi, Hubei 05, 2017 JS3 
 Jianshi, Hubei 05, 2017 JS4 
 Jianshi, Hubei 05, 2017 JS5 
 Jianshi, Hubei 05, 2017 JS6 
 Xuan’en, Hubei 05, 2017 XE1 
 Xuan’en, Hubei 05, 2017 XE2 
 Xuan’en, Hubei 05, 2017 XE3 
 Xuan’en, Hubei 05, 2017 XE4 
 Xuan’en, Hubei 05, 2017 XE5 
 Xuan’en, Hubei 05, 2017 XE6 
 Badong, Hubei 05, 2017 BD1 
 Badong, Hubei 05, 2017 BD2 
 Badong, Hubei 05, 2017 BD3 
 Badong, Hubei 05, 2017 BD4 
 Badong, Hubei 05, 2017 BD5 
 Badong, Hubei 05, 2017 BD6 
 Hefeng, Hubei 05, 2017 HF1 
 Hefeng, Hubei 05, 2017 HF2 
 Hefeng, Hubei 05, 2017 HF3 
 Hefeng, Hubei 05, 2017 HF4 
 Hefeng, Hubei 05, 2017 HF5 
 Hefeng, Hubei 05, 2017 HF6 
 Dujiangyan, Sichuan 05, 2017 DJY1 
 Dujiangyan, Sichuan 05, 2017 DJY2 
 Dujiangyan, Sichuan 05, 2017 DJY3 
 Dujiangyan, Sichuan 05, 2017 DJY4 
 Dujiangyan, Sichuan 05, 2017 DJY5 
a. Chuan po and Wen po are MOC samples derived from Magnolia officinalis Rehd. et Wils. (MO) and M. 
officinalis Rehd. et Wils. var. biloba Rehd. et Wils. (MOB), respectively.  
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Table 3.7 (Continued) 
Chuan po 
a





Qingyuan, Zhejiang 04, 2016 QY1 
Qingyuan, Zhejiang 04, 2016 QY2 
Qingyuan, Zhejiang 04, 2016 QY3 
Qingyuan, Zhejiang 04, 2016 QY4 
Qingyuan, Zhejiang 04, 2016 QY5 
Qingyuan, Zhejiang 04, 2016 QY6 
Minhou, Fujian 04, 2016 MH1 
Minhou, Fujian 04, 2016 MH2 
Minhou, Fujian 04, 2016 MH3 
Minhou, Fujian 04, 2016 MH4 
Minhou, Fujian 04, 2016 MH5 
Minhou, Fujian 04, 2016 MH6 
Wuyishan, Fujian 04, 2017 WYS1 
Wuyishan, Fujian 04, 2017 WYS2 
Wuyishan, Fujian 04, 2017 WYS3 
Wuyishan, Fujian 04, 2017 WYS4 
Wuyishan, Fujian 04, 2017 WYS5 
Wuyishan, Fujian 04, 2017 WYS6 
a. Chuan po and Wen po are MOC samples derived from Magnolia officinalis Rehd. et Wils. (MO) and M. 




























Table 3.8 Data sets of quantitative profiles of magnoloside obtained from 2LC-ECD measurement for 
multivariable analysis 
MOC sample  Contents of magnolosides (mg/g) 
 # A B D F H L M 
Chuan po JS1 21.44 16.81 0.18 7.83 2.76 2.79 1.87 
JS2 12.02 45.72 0.07 13.30 5.35 1.51 1.11 
JS3 16.25 13.26 0.23 4.43 2.57 2.60 2.87 
JS4 11.51 31.49 0.12 8.87 3.80 1.88 1.14 
JS5 3.36 42.54 0.11 9.48 5.55 1.04 0.52 
JS6 12.25 38.46 0.09 10.93 5.13 2.00 0.99 
ES1 42.06 8.39 0.22 8.29 1.28 5.46 6.75 
ES2 30.39 8.56 0.15 6.27 1.23 3.99 4.82 
ES3 20.71 39.21 0.13 12.92 4.69 2.93 2.30 
ES4 38.43 11.80 0.21 9.48 2.07 4.97 5.29 
ES5 23.01 16.55 0.09 8.25 2.47 3.02 1.64 
ES6 15.06 16.76 0.06 7.34 2.25 2.11 0.66 
XE1 29.01 17.36 0.10 10.09 2.47 4.11 2.36 
XE2 9.12 6.50 0.05 3.32 1.06 1.11 0.69 
XE3 10.99 17.77 0.06 6.27 2.12 1.39 0.77 
XE4 13.29 19.49 0.04 7.80 3.08 1.93 0.69 
XE5 22.93 1.95 0.19 2.48 0.96 3.13 4.80 
XE6 26.97 10.15 0.08 6.96 2.02 4.23 3.49 
BD1 15.97  17.73  0.10  6.96  4.47  2.04  2.04  
BD2 22.93  12.19  0.10  5.92  4.27  3.06  3.59  
BD3 23.84  13.97  0.09  6.88  4.69  3.02  2.94  
BD4 7.46  6.48  0.06  1.87  1.68  1.14  1.50  
BD5 13.72  20.54  0.06  7.34  4.27  2.02  0.91  
BD6 24.29  8.82  0.09  5.69  2.71  2.88  3.16  
HF1 34.77  3.78  0.26  7.57  4.86  4.11  3.93  
HF2 25.58  4.31  0.10  4.36  4.81  3.25  4.47  
HF3 28.58  13.69  0.06  9.55  3.73  3.09  1.90  
HF4 32.24  6.37  0.13  6.99  4.24  3.58  3.84  
HF5 20.71  4.92  0.10  5.16  5.40  2.18  1.54  
HF6 13.25  3.84  n.d.  3.21  2.07  1.72  1.94  
DJY1 5.57  33.96  0.07  8.67  4.71  1.14  0.69  
DJY2 29.69  31.72  0.06  15.78  3.21  3.83  1.62  
DJY3 8.42  37.11  0.09  9.55  4.64  1.45  0.70  
DJY4 7.93  41.96  0.06  10.59  3.58  1.16  0.81  




Table 3.8 (Continued) 
MOC sample  Contents of magnolosides (mg/g) 
 # A B D F H L M 
Chuan po DJY5 12.72  43.10  0.09  12.42  3.97  1.86  1.15  
DJY6 3.42  36.08  0.09  9.25  3.97  0.65  0.28  
Wen po QY1 15.16 29.51 n.d. 9.55 4.12 1.83 0.66 
QY2 8.32 29.21 n.d. 9.13 4.29 1.93 0.17 
QY3 4.64 24.02 n.d. 9.13 3.85 0.95 0.20 
QY4 10.36 21.18 n.d. 8.06 4.15 1.30 0.16 
QY5 5.59 16.03 n.d. 6.04 2.74 0.60 0.20 
QY6 8.68 38.63 n.d. 10.13 5.03 1.04 0.23 
MH1 14.35  21.76  n.d. 7.53  3.01  1.09  1.14  
MH2 15.10  25.73  n.d. 8.60  6.27  1.74  1.44  
MH3 9.74  20.97  n.d. 5.73  4.56  0.65  0.85  
MH4 18.54  8.54  n.d. 4.97  7.40  1.72  2.08  
MH5 28.18  14.90  n.d. 7.87  5.23  2.39  4.10  
MH6 11.95  12.17  n.d. 4.70  3.36  1.11  1.31  
WYS1 4.78  37.78  n.d. 8.60  7.40  0.86  0.39  
WYS2 2.91  34.21  n.d. 7.49  9.06  0.44  0.37  
WYS3 2.45  42.84  n.d. 9.10  9.55  0.42  0.42  
WYS4 1.17  43.70  n.d. 10.09  9.25  0.42  0.30  
WYS5 1.17  43.68  n.d. 9.74  13.45  0.42  0.32  
WYS6 5.81  28.87  n.d. 7.64  8.07  0.51  0.59  
n.d., not detected. 
 
The quantitative results of PhGs content were subjected to statistical analysis. Firstly, one-way 
analysis of variance (ANOVA) was used to compare the mean content of each PhG between 36 
batches of Chuan po and 18 batches of Wen po in Fig. 3.6. The contents of magnolosides A, L, 
and M in Chuan po were abundant compared with those in Wen po, while the contents of 
magnolosides B and H in Wen po were abundant compared to those in Chuan po. The content of 
magnoloside D in Chuan po was 0.11 ± 0.01 mg/g (means ± standard error, SE), however, 
magnoloside D was hardly detected in Wen po by the 2LC-ECD. Amongst the contents of 
magnolosides A, B, D, H, L, and M between Chuan po and Wen po, there was a significant 




Fig. 3.6 Each PhG content of mean (±SE) in 36 batches of Chuan po and 18 batches of Wen po. (Significant 
difference in the test of one-way ANOVA: †, p < 0.05; ‡, p < 0.01; *, p < 0.001.) 
 
3.2.3 Discrimination of Magnoliae Officinalis Cortex Using Multivariable Analysis 
Multivariate statistical methods were applied to the analysis of LC-ECD data to discriminate 
and classify Chuan po as well as Wen po. Both unsupervised principal component analysis (PCA) 
and a supervised partial least squares discriminant analysis (PLS-DA) were carried out using 
SIMCA-P Version 11.5 software (Umetrics AB, Umea, Sweden) to analyze the results of the 
PhGs determinations. All the variables were Log-transformed and Pareto-scaled prior to PCA and 
PLS-DA. PCA takes a data matrix of n objects by p variables which may be correlated, and 
summarizes the matrix by uncorrelated axes (principal components) that are linear combinations 
of the original p variables [80, 81]. The PCA was used to explore the overall sample distribution 
trends for factors such as aggregation, dispersion, and outliers. PLS-DA, a supervised 
classification technique, can maximize the difference among the groups [82, 83]. Furthermore, 
the VIP-plot was generated from the PLS-DA model to screen the variables with the largest 





which respectively represented the fraction of the variance of the X matrix and the Y matrix, and 
Q
2
 defined as the proportion of variance in the data predicted by the model. 
Firstly, the obtained multivariate dataset were analyzed by PCA. The score plot of PCA is 
given in Fig. 3.7. The scatter plot indicated that XE5 and HF6 were out of ellipse of the 95% 
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confidence interval and BD4 and XE2 were dispersed away from the group of Chuan po, so the 
four outliers were rejected in the following analysis. Moderate separation of the two groups was 
observed on the new PCA score plot in Fig. 3.8A, the first principal component (PC1) and 
second one (PC2) explained approximately 81.68% of the total variability (i.e., 67.94% and 
13.74% for PC1 and PC2, respectively). Then, the multivariate dataset was imported for the 
PLS-DA. As a result, the model described 91.5% of the variations in the response Y (class) (R
2
Y 
= 0.915) which also predicted 90.0% of the variations in the response Y (Q
2
 = 0.9). Therefore, 
the model presented satisfied classification ability among the two groups of MOC. As shown in 
Fig. 3.8B, Chuan po and Wen po were clearly separated from each other on the PLS-DA score 
plot. Meanwhile, the goodness of fit and the predictability of this model were validated by a 
chance permutations test (n = 200). As shown in Fig. 3.8C, the intercept value of R
2
 (0.0, 0.0235) 
was < 0.3 and Q
2
 (0.0, -0.342) was < 0.05, which indicated a statistical significance and no 
over-fitting with high predictive value of the model. With supervised PLS-DA, identification of 
discriminatory variables proceeds from an analysis of the PLS weights. In order to weigh the 
effect of importance of every variable on discrimination, the VIP plots were employed to screen 
the potential discriminant variables for discrimination as shown in Fig. 3.8D. According to the 
VIP plot, several variables had VIP-values larger than 1, which meant that these variables were 
primarily responsible for the discrimination. Among them, variables magnolosides D and M had 
the largest VIP-values of 1.78 and 1.02, respectively. 
 
 
Fig. 3.7 PCA score plot of all MOC samples (t[x] refers to the score of the x
th
 principal component; 
observations were marked according to the name of the habitat: ES, Enshi; JS, Jianshi; XE, Xuan’en; BD: 





Fig. 3.8 Multivariable analyses for the classification of MOC samples based on the results of magnoloside 
profiles by 2LC-ECD. (A) Unsupervised PCA score plot of MOC samples without four outliers (t[x] refers to 
the score of the x
th
 principal component, PC1: 67.94%, PC2: 13.74%; observations were marked according to 
the name of the habitat: ES, Enshi; JS, Jianshi; XE, Xuan’en; BD, Badong; HF, Hefeng; DJY, Dujiangyan; QY, 
Qingyun; MH, Minhou; WYS, Wuyishan. (B) PLS-DA score plot of MOC samples [R
2
X = 0.886 R
2
Y = 0.915 
and Q
2
 (cum) = 0.9]; (C) A chance permutation test at 200 times used to validate the occurrence or absence of 
over-fitting of the PLS-DA mode [R
2
 = (0.0, 0.0235), Q
2
 = (0.0, -0.342)] (D) VIP (variable importance for the 
project) plot of PLS-DA of MOC samples (error bar is marked in every variable). 
 
Chemical studies focused on habitat and variety of MOC have been mainly based on the 
profile of magnolol and honokiol [84-87]. The total content of magnolol and honokiol (TMH) in 
MO produced in Hubei was generally higher than that of the same variety from other habitats, 
and the TMH in MOB produced in Zhejiang was lower than that of the same variety from other 
habitats [84], which indicated that the contents of TMH in MOC from different habitats were 
different. Our previous study also determined the contents of magnolosides A and B in MOC 
from different habitats using LC-DAD, although no statistical methods were achieved to 
demonstrate the relationship between the habitat and content of PhGs due to the limited chemical 
determinants, differences in the content of magnolosides A and B among habitats were found 
[79]. Through our current study, the discrimination between Chuan po and Wen po was found 
based on the profiling of more PhGs. The results also further verified that the content of PhGs in 
the MOC samples from the various habitats were different. 
In this chapter, a 2LC-ECD system with high sensitivity has been developed for the 
simultaneous determination of seven PhGs in MOC. By the use of the 2LC-ECD, the analytical 
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time for determining seven PhGs was remarkably reduced compared with that of a single 
channel isocratic LC-ECD. To the best of our knowledge, the present study is the first report that 
the determination of magnolosides D, F, H, L, and M in MOC has been provided by means of 
liquid chromatography. Furthermore, a multivariable analysis technique was provided to 
discriminate Chuan po and Wen po based on the quantitative profiles of PhGs obtained by the 
2LC-ECD. Based on the results of PCA and PLS-DA, it was found that magnolosides D and M 
were the important variables to help discriminate the MOC samples of Chuan po and Wen po 







































Chapter 4  Rapid Profiling of Phenylethanoid Glycosides in Magnoliae Officinalis Cortex 
by UHPLC-QTOF/MS 
 
PhGs with structural diversity were found to exist in MOC [9, 41], and some PhGs showed 
more potent α-glucosidase inhibitory effects than acarbose and moderate cytotoxic effects [41], 
as well as significant protective effects against free radical-induced oxidative damage [9]. To 
comprehensively elaborate the PhGs in MOC and lay the foundation for subsequent study 
focused on discovery of new lead components, a systematic qualitative analysis regarding PhGs 
were performed. 
Sustainable efforts have been devoted to characterize natural products utilizing the powerful 
tools of combinations of different types of MS with chromatography [20-22]. In this chapter, 
UHPLC-QTOF/MS, which has the virtues of accurate mass measurement, high throughput and 
supplying the guarantee of exact classification of ions, was applied to obtain rapid profiling of 
PhGs from MOC. In addition, the MS
E
 analysis, which can acquire the exact mass of precursor 
and abundant fragment ions in a single analytical injection, was also performed, in which two 
alternative scan functions with switched collision energies are acquired: low collision energy to 
obtain precursor ion information, and high collision energy to obtain information regarding the 
abundant fragment ions and/or neutral loss information. A method of multiple DINL postanalysis 
is proposed to characterize PhGs from MOC. The proposed strategy is shown in Fig. 4.1. First, 
the characteristic product ions and neutral loss for structural information were induced based on 
24 reference standards; subsequently, the major structural type of PhGs in the sample were 
filtered manually and by UNIFI and then characterized from the entire MS
E
 profile; finally, 101 
PhGs were discovered from MOC. Most of these PhGs were potentially novel compounds, and 
17 PhGs were unambiguously identified by comparing the retention time and MS
E
 data with 
those of reference compounds. 
 
 
Fig. 4.1 Summary diagram for identification of PhGs by UHPLC-QTOF/MS 
52 
 
4.1 Development of UHPLC-QTOF/MS for Qualitative Analysis of Phenylethanoid 
Glycosides 
 
4.1.1 Chemicals and Reagents 
Authentic standard compounds echinacoside, poliumoside and salidroside were purchased 
from Shanghai tongtian biotechnology Co., Ltd (Shanghai, China); plantamajoside, forsythoside 
B, forsythoside A, acteoside and isoacteoside were purchased from Chengdu pusi biotechnology 
Co., Ltd (Shanghai, China); their purities were above 98%. Reference compounds magnoloside 
N, magnoloside B, magnoloside H, magnoloside G, magnoloside F, magnoloside A, 
magnoloside L, magnoloside I, magnoloside K, magnoloside J, magnoloside O, magnoloside P, 
magnoloside M, magnoloside E, magnoloside D, 2-(3,4-dihydroxyphenyl) ethanol 
1-O-[4-O-caffeoyl-2-O-α-L-rhamnopyranosyl-3-O-α-L-rhamnopyranosyl-6-O-β-D-glucopyranosy
l]-β-D-glucopyranoside were isolated from MO by ourselves, their purity of each reference 
compound was determined to be more than 90% by normalization of the peak areas detected by 
LC-UV [41]. All the standards’ structures are given in Fig. 4.2. 
MeCN and MeOH of LC-MS grade were obtained from Merck (Darmstadt, Germany). 
LC-MS grade FA was obtained from Fisher Scientific (Belgium). Ultra-pure water (18.2 MΩ 
cm
-1





Fig. 4.2 Structures of reference compounds. Magnoloside N (1A), magnoloside B (2A), magnoloside H (3A), 
magnoloside G (4A), magnoloside F (5A), magnoloside A (6A), magnoloside L (7A), magnoloside I (8A), 
magnoloside K (9A), magnoloside J (10A), magnoloside O (11A), magnoloside P (12A), magnoloside M 
(13A), magnoloside E (14A), magnoloside D (15A), salidroside (1G), 2-(3,4-dihydroxyphenyl) ethanol 
1-O-[4-O-caffeoyl-2-O-α-L-rhamnopyranosyl-3-O-α-L-rhamnopyranosyl-6-O-β-D-glucopyranosyl]-β-D-glucopy
ranoside (2G), echinacoside (3G), plantamajoside (4G), forsythoside B (5G), forsythoside A (6G), acteoside 
(7G), poliumoside (8G), isoacteoside (9G). 
 
4.1.2 UHPLC-QTOF/MS Conditions 
Since traditional columns have difficulty in baseline separation of polar compounds, the 
reversed C18 analytical column (2.1 mm × 100 mm, 1.8 μm, ACQUITY UPLC
®
T3, Waters, 
USA) coupled with a C18 precolumn (2.1 mm × 10 mm, 1.8 μm, VanGuard
TM
 T3, Waters, USA) 
was adopted and a high temperature of 40°C was applied to overcome the high pressures during 
the high proportion of water. To obtain satisfying chromatographic separation and high quality 
MS
E
 data for PhGs, optimized gradient elution was adopted. The mobile phases were 0.1% (v/v) 
FA aqueous solution (A) and 0.1% (v/v) FA MeCN (B) with the following gradient: 5–20% B 
(0–12 min), 20–40% B (12–13 min), 40–60% B (13–15 min), 60–70% B (15–18 min), 70–90% 
B (18–23 min). The equilibration time and the flow rate were set at 4 min and 0.5 mL/min, 
respectively. The injection volume of the sample was 1 μL. The temperature of the auto-sampler 
chamber was set at 4°C. 
Metabolites profiling was performed on a Waters Xevo G2-S QTOF/MS (Waters Micromass, 
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Manchester, UK) operated in negative electrospray ionization mode. Although MOC exhibited 
only several major peaks of PhGs in UHPLC-QTOF/MS analysis, a number of minor 
compounds could be observed in the enlarged chromatogram (Fig. 4.3-4.5). The QTOF/MS 
parameters were set as follows: mass range, 100–1200 Da; scan time, 0.15 s; capillary voltage, 
2.0 kV; cone voltage, 40 V; source temperature, 100°C; desolvation gas temperature, 450°C; 
cone gas flow rate, 50 L/h; and desolvation flow rate, 900 L/h. Collision energies were set at a 
low energy of 6 eV for the precursor ions and an optimal high energy ramp of 35 to 60 eV for 
fragmentation information. The molecular masses of the precursor ion and product ions were 
accurately determined with leucine-enkephalin (m/z 554.2615 in negative electrospray ionization 
mode) at a concentration of 200 pg/L and an infusion flow rate of 20 μL/min. Data acquisition 
was controlled by MassLynx V4.1 software (Waters Corporation, Milford, USA). For 




 data were acquired in Continnum format. 
 
 
Fig. 4.3 UHPLC-MS chromatograms of MOC (QC sample). (A) Base peak ion chromatogram (BPI); (B) 




Fig. 4.4 Chromatograms of flower of MO from Enshi. (A) Base peak ion chromatogram (BPI); (B) Enlarged 
BPI. (Compounds only characterized in flower were labeled) 
 
 
Fig. 4.5 Chromatograms of leaf of MO from Enshi. (A) Base peak ion chromatogram (BPI); (B) Enlarged BPI. 
(Compounds only characterized in leaf were labeled) 
 
4.1.3 Data Mining 
The process was to extract PhG compounds from a full scan profile using the diagnostic 
ions and neutral loss. Data were processed through EIC manually and by UNIFI 1.8 (Waters, 
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Milford, USA): 1) Diagnostic ions of the five subtypes of PhGs were picked from the MS/MS 
data of 24 reference compounds; 2) These ions were extracted from a full scan mass spectrum of 
the sample manually to efficiently identify the substructures for each cycle. To identify the 
coeluting peaks and reduce the false positive results, two filters of both “common fragment” and 
“common neutral loss” were simultaneously used to extract PhGs by UNIFI 1.8 (Waters, Milford, 
USA); 3) Corresponding profiles for each peak to the 5 EICs and the preliminary output 
characterization results of UNIFI were recorded; 4) Substructures were recognized by comparing 





4.2 UHPLC-QTOF/MS Analysis for Phenylethanoid Glycosides in Magnoliae Officinalis 
Cortex 
 
4.2.1 Plant Materials and Sample Preparation 
Raw bark samples were collected from eight habitats (Songtao, Xishui, Ziyuan, Enshi, 
Jingning, Qingyun, Yuexi, and Jinggangshan) in China. Flower and leaf were collected from 
Enshi. All of the voucher samples were authenticated by the authors and deposited in the 
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences (Beijing, 
China). 
The samples were powdered to a homogeneous size and sieved through a No. 50 mesh. The 
accurately weighed dried powders (0.1 g) were dissolved in 1.5 mL of 70% (v/v) MeOH aqueous 
and ultrasonically extracted for 30 min at 35°C and 100 kHz to prepare the sample solutions. 
After being centrifuged at 20630 g for 10 min, the supernatants of the sample solutions were 
subsequently filtered through a 0.2 μm GHP filter (PALL, USA) and stored at 4°C until further 
study. Meanwhile, undiluted extracts of stems from 8 habitats were mixed and subjected to 
qualitative characterization, as well as samples of flower and leaf from Enshi. 
 
4.2.2 Fragmentation Rules of Phenylethanoid Glycosides 
PhGs have been most widely studied in families of Scrophulariaceae (e.g. Rehmannia 
glutinosa Libosch.), Plantaginaceae (e.g. Plantago asiatica L.), Orobanchaceae (e.g. Cistanche 
deserticola Y.C. Ma, C. tubulosa) and so forth [33], and recently found as the primary chemical 
classes in MOC. Backed by the great convenience provided by DINLs scanning for compound 
retrieval and chemical identification, authentic compounds complemented by the cracking rules 
archived in the literature were simultaneously employed to summarize the DINLs for the PhG 
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compounds. The MS spectra of 24 reference compounds isolated from MO were analyzed using 
UHPLC-QTOF/MS. According to the types of aromatic acids substituted to the core sugar, the 
24 reference compounds could be classified into five types: caffeoyl (Caff), feruloyl (Feru), 
coumaroyl (Coum), vanilloyl (Vani) and syringoyl (Syr)-substituted, which could yield 
diagnostic fragment ions of m/z 161.0239, 175.0395, 145.0290, 465.1397 and 495.1503, 
respectively, meanwhile the first three subtypes could also generate characterized neutral loss of 
162.0317 Da, 176.0473 Da and 146.0368 Da. The above results thereby verified the applicability 
of some fragmentation rules recorded in literature. Representative structures and their 
chromatograms as well as fragmentation pathways are shown in Fig. 4.6. 
 
 
Fig. 4.6 Representative MS spectra of PhGs of Caff/Feru/Coum-type and Vani/Syr-type and their proposed 
fragmentation pathways. (A) Caff-type (magnoloside H); (B) Feru-type (magnoloside K); (C) Coum-type 
(magnoloside I); (D) Vani-type (magnoloside P); (E) Syr-type (magnoloside O). (Caff: caffeoyl, Feru: feruloyl, 
Coum: coumaroyl, Vani: vanilloyl, Syr: syringoyl.) 
 
4.2.3 Extraction and Characterization of Phenylethanoid Glycosides in Magnoliae 
Officinalis Cortex 
PhG compounds were firstly extracted from the second-order MS
E
 spectral data obtained 
using MOC samples after the high-resolution diagnostic fragment ions were set down. Their 
extract ion chromatograms (EICs) are shown in Fig. 4.7, the conservative substructures could be 
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rapidly and efficiently recognized. High-resolution was critical for extraction of diagnostic ions 
to reduce false-positive signals. For the reference compounds, their MS
E
 mass errors were less 
than 5 ppm or 5 mDa. Therefore, the extraction width for diagnostic ions was extended to ±10 
ppm or ± 10 mDa [34].  
Structures of the recognized compounds were further identified by analyzing their 
high-resolution MS
E
 spectra. After the moiety of aromatic acid was distinguished, there were 
still two steps left to identify a PhG, i.e., identification of sugar moieties and aglycone. After the 
neutral losses of aromatic acid were excluded, the following neutral loss of 162.0528 Da usually 
stands for a hexose, for example, glucose or allose; the neutral loss of 146.0579 Da usually 
stands for a rhamnose, and the neutral loss of 132.0423 Da usually represents a pentose, for 
example, apiose [88, 89]. After the sugar moieties were identified, the aglycone moiety could be 
characterized according to its corresponding ions. m/z 315.1080 and 135.0446 were yielded from 
3-hydroxy-salidroside and hydroxytyrosol, which indicated the existence of aglycone of 
hydroxytyrosol; product ions of m/z 299.1131 and 137.0603 yielded from salidroside and tyrosol 
showed that the aglycone was tyrosol; the same situation also applied for product ions of m/z 
283.1182 and 121.0653, which indicated the existence of aglycone of dehydroxy tyrosol.  
 
 
Fig. 4.7 EICs of MOC sample in (−)-ESI: (A) EIC m/z 161.022, 10 ppm; (B) EIC m/z 145.027, 10 ppm; (C) 
EIC m/z 175.037, 10 ppm; (D) EIC m/z 465.137, 10 ppm; (E) EIC m/z 495.149, 10 ppm. Compounds 
confirmed by reference compounds were marked in red, identified by EIC method were marked in blue, and 
identified by UNIFI were marked in black. 
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Then, the structures of PhGs were preliminarily characterized through the identification of 
aromatic acid, sugar and aglycone moieties. Fig. 4.8 lists the main aglycone, aromatic acid and 
saccharide types of PhGs in MOC. Through manual extraction of the diagnostic ions, 73 PhGs in 
total including 55 PhGs of Caff-type, 3 PhGs of Feru-type, 8 PhGs of Coum-type, 1 PhGs of 
Vani-type, 1 PhGs of Syr-type and 5 PhGs of other types without aromatic acid moieties were 
characterized. Most PhGs were compounds of Caff-type and had an aglycone of hydroxytyrosol. 
In addition, compounds 5, 17, 23, 27, 31-34, 36, 39, 43, 46, 51, 65, 68, 76 and 82 were 
unambiguously identified as salidroside, magnolosides N, B, H, G, F, A, L, I, K, J, 
2-(3,4-dihydroxyphenyl) ethanol 
1-O-[4-O-caffeoyl-2-O-α-L-rhamnopyranosyl-3-O-α-L-rhamnopyranosyl-6-O-β-D-glucopyranosy




Fig. 4.8 Main aglycone, aromatic acid and saccharide groups of PhGs in MOC 
 
EIC performed manually was sometimes flawed in characterization of coeluting peaks. 
Resorting to the core-idea of database retrieval, the automated UNIFI software was able to 
dramatically accomplish chromatographic peak detection, molecular formula prediction, MS/MS 
fragment matching, preliminary chemical characterization, and especially could characterize the 
coeluting ingredients almost independent of human assistance
 
[90]. Then UNIFI was used for 
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automated extracting PhG compounds from the dataset acquired by the MS
E
 scan mode with the 
assistance of an in-house TCM library. The retention time of 24 reference compounds was added 
to the TCM library to achieve their unambiguous characterization in different samples, and the 
English name and molecular formula of 69 PhGs and phenolic glycosides that were ever isolated 
or characterized from MOC (up to 2018) were involved. All the structure files were prepared 
using ChemBioDraw 14.0 and then saved as a .mol file individually. Considering the relatively 
low accurate rate of UNIFI by only one filtering, to reduce the false positive results, two filtering 
of “common fragment” and “common neutral loss” were simultaneously utilized to efficiently 
characterize other potentials. Key parameters within UNIFI were set as follows: peak detection 
time, 0–15 min; intensity threshold, 200 and 25 counts for low energy and high energy 
acquisitions, respectively; mass accuracy, ±10 ppm; and retention time window, ± 0.2 min. 
Based on the illustration in Fig. 4.6B, groups of caffeoyl, feruloyl and coumaroyl were able to 
produce characteristically diagnostic ions of m/z 161.0239, 175.0395, 145.0290 and neutral loss 
of 162.0317 Da, 176.0473 Da and 146.0368 Da. Simultaneously using the two filters of 
“common fragment” and “common neutral loss”, a total of 53 compounds were extracted from 
the profile and 50 compounds were further characterized as PhGs according to their detailed 
MS
E
 data. The accuracy rate of 94.34% was much higher than that of using only “common 
fragment” or “common neutral loss”, in which the accuracy rates were 24.54% and 68.75%, 
respectively. Combined with the two filters of “common fragment” and “common neutral loss”, 
in addition to the repeated compounds characterized from EICs, 28 other unknown compounds 
24, 26, 37, 40, 41, 47-50, 52, 53, 56, 60, 62, 67, 69, 70, 74, 77, 78, 81, 86, 87, 95, 96, and 98–
100 were identified or putatively characterized as PhGs using the UNIFI method. Most 
compounds such as compounds 24, 53, 74 and 77 were the coeluting peaks to compounds 25, 54, 
73 and 78. The above results showed the UNIFI method could complement the method of 
manually extracting characteristic ions. 
The scanning of DINL was established to rapidly characterize PhGs from MOC. Eight DINL 
scans based on characteristic ions were used to extract the PhGs, ultimately, 101 PhGs were 
identified or putatively characterized from MOC and 17 PhGs were unambiguously identified by 
comparing the retention time and MS/MS data with those of reference compounds (Table 4.1). 
Compounds 1, 23, 27, 32-34, 54, 57, 61, 68, 76, 79, 82-83 and 90 were the shared compounds 
among bark, leaf and flower, and compounds 58, 78, 87, 89 and 91, the aglycone of which was 




Table 4.1 Characterization of PhGs in MOC by UHPLC−QTOF/MS 
No tR (min) Formula m/z (observed) m/z (calc.) Δ (mDa) Adducts (−)-ESI-MS/MS (m/z) Component name B F L 
Caff-type (55) 
6 3.14 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1576, 315.1081, 161.0218 PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
7 3.22 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 461.1607, 315.1081, 161.0218 PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
8 3.88 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1576, 461.1519, 315.1044, 
161.0218 
PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
9 4.06 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1576, 461.1651, 315.1081, 
161.0218 
PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
10 4.14 C41H55O25 947.3075 947.3032 4.3 -H 785.2517, 623.2175, 477.1576, 461.1651, 
161.0218 
PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
11 4.53 C47H65O30 1109.3584 1109.3561 2.1 -H 947.3327, 785.2632, 639.2051, 477.1576, 
161.0218 
PG+Caff +3Glc+Rha √   
12 4.68 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1044, 161.0218 PG+Caff+Rha 
Isomer of magnoloside A or 
M or D 
√ √  
13 4.85 C29H37O16 641.2055 641.2082 2.7 -H+H2O 461.1607, 315.1044, 161.0218 PG+Caff+Rha √   
14 4.99 C35H45O20 785.2517 785.2504 1.3 -H 623.2072, 477.1576, 461.1651, 315.1008, 
161.0218 
PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
15 5.31 C41H55O25 947.3075 947.3032 4.3 -H 785.2747, 639.2103, 623.2225, 461.1607, 
315.1044, 161.0218 
PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
16 5.49 C41H55O25 947.3075 947.3032 4.3 -H 785.2632, 623.2225, 477.1531, 161.0192 PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
17* 5.60 C41H55O25 947.3075 947.3032 4.3 -H 785.2574, 623.2225, 477.1620, 161.0218 Magnoloside N* √   
18 5.76 C35H45O21 801.2479 801.2453 2.6 -H 639.2155, 477.1576, 161.0218 PG+Caff+2Glc √   
19 5.90  C40H53O25 933.2894 933.2876 1.8 -H 771.2360, 609.2003, 477.1620, 315.1008, 
161.0218 
PG+Caff+2Glc+Api √   
20 6.05 C41H55O25 947.3075 947.3032 4.3 -H 785.2747, 623.2225, 477.1620, 161.0218, 
135.0431 
PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
21 6.17 C35H45O21 801.2479 801.2453 2.6 -H 639.2155, 477.1576, 315.1044, 161.0218, 
135.0407 
PG+Caff+2Glc √   
22 6.24 C41H55O25 947.3075 947.3032 4.3 -H 785.2747, 623.2175, 477.1576, 161.0218, 
135.0407 
PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
23* 6.36 C35H45O20 785.2517 785.2504 1.3 -H 623.2225, 477.1620, 161.0218 Magnoloside B* √   
25 6.53 C35H45O20 785.2517 785.2504 1.3 -H 623.2072, 461.1651, 315.1081, 161.0218, 
135.0407 
PG+Caff+Glc+Rha √   
27* 6.67 C34H43O20 771.2360 771.2348 1.2 -H 609.2053, 477.1620, 315.1081, 161.0218, 
135.0407 




No tR (min) Formula m/z (observed) m/z (calc.) Δ (mDa) Adducts (−)-ESI-MS/MS (m/z) Component name B F L 
28 6.90 C29H35O16 639.1948 639.1925 2.3 -H 477.1576, 161.0218 PG+Caff+Glc √   
29 7.15 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 461.1651, 315.1044, 161.0218, 
135.0407 
Magnoloside B isomer 
PG+Caff+Glc+Rha 
√   
30 7.21 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1620, 461.1607, 315.1044, 
161.0218 
PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
31* 7.29 C34H43O20 771.2360 771.2348 1.2 -H 609.2053, 477.1576, 315.1081, 161.0218, 
135.0407 
Magnoloside G* √ √ √ 
32* 7.50 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1576, 315.1044, 161.0218, 
135.0407 
Magnoloside F* √   
33* 7.62 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1044, 161.0218, 135.0407 Magnoloside A* √   
34* 7.75 C28H33O15 609.1801 609.1819 1.8 -H 447.1499, 315.1081, 161.0218, 135.0407 Magnoloside L* √   
35 7.91 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1576, 161.0218, 135.0407 Magnoloside B isomer 
PG+Caff+Glc+Rha 
√   
38 8.20 C35H45O20 785.2531 785.2504 2.7 -H 623.2234, 461.1584, 315.1046, 161.0189 PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
42 8.44 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 477.1620, 161.0218, 135.0431 PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√ √ √ 
43* 8.46 C36H47O20 799.2663 799.2661 0.2 -H 637.2234, 491.1868, 329.1423, 161.0218 Magnoloside J* √ √ √ 
44 8.54 C29H35O16 639.1940 639.1925 1.5 -H 477.1537, 315.1082, 161.0215 PG+Caff+Glc √ √  







√   
55 9.31 C23H25O11 477.1397 477.1397 0.0 -H 315.1008, 161.0218 PG+Caff √   
58 9.53 C41H55O23 915.3132 915.3134 0.2 -H 753.2811, 607.2226, 445.1722, 299.1135, 
161.0189 
LG+Caff+2Rha+Glc √   
57 9.45 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1044, 161.0218 Isolugrandoside isomer
14 
PG+Caff+Rha 
√   
59 9.55 C41H55O23 915.3125 915.3134 0.9 -H 753.2767, 607.2354, 461.1563, 315.1081, 
161.0218 
PG+Caff+3Rha √   





√   




No tR (min) Formula m/z (observed) m/z (calc.) Δ (mDa) Adducts (−)-ESI-MS/MS (m/z) Component name B F L 
66 9.88 C35H45O20 785.2517 785.2504 1.3 -H 623.2072, 477.1576, 315.1008, 161.0218 PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
68* 10.33 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1044, 161.0218 Magnoloside M* √   
71 10.69 C29H35O15 623.1978 623.1976 0.2 -H 477.1940, 461.1672, 315.1046, 161.0189 PG+Caff+Rha 
Isomer of magnoloside A or 
M or D 
√   
75 10.91 C35H45O20 785.2517 785.2504 1.3 -H 623.2175, 461.1607, 315.1081, 161.0218, 
135.0407 
PG+Caff+Glc+Rha √   
76* 11.11 C28H33O15 609.1801 609.1819 1.8 -H 447.1499, 315.1081, 161.0218, 35.0407 Magnoloside E*  √   
79 11.32 C35H45O19 769.2551 769.2555 0.4 -H 607.2226, 461.1672, 315.1046, 161.0215, 
135.0405 
PG+Caff+2Rha √   
80 11.37 C35H45O19 769.2551 769.2555 0.4 -H 607.2226, 461.1672, 315.1046, 161.0215 PG+Caff+2Rha  √  
82* 11.67 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1044, 161.0218, 135.0407 Magnoloside D* √   
85 12.17 C35H45O19 769.2551 769.2555 0.4 -H 607.2226, 461.1672, 315.1046, 161.0215, 
135.0405 
PG+Caff+2Rha √ √ √ 
89 12.96 C29H35O13 591.2058 591.2078 2.0 -H 161.0189 Tyrosol+Caff+2Rha √   
91 13.40 C29H35O13 591.2058 591.2078 2.0 -H 161.0189 Tyrosol+Caff+2Rha  √  
92 13.86 C35H45O20 785.2517 785.2504 1.3 -H 623.2072, 477.1665, 461.1651, 315.1008, 
161.0218 
PG+Caff+Glc+Rha   √ 
93 13.94 C35H45O20 785.2460 785.2504 4.4 -H 623.2175, 477.1576, 461.1695, 315.1081, 
161.0218 
PG+Caff+Glc+Rha 
Isomer of magnoloside B or F 
√   
94 14.00 C35H45O20 785.2460 785.2504 4.4 -H 623.2123, 477.1576, 461.1695, 315.1044, 
161.0218, 135.0407, 478.1538, 279.0862, 
262.0795, 179.0555, 147.0409, 477.1605, 
161.0237, 221.0660, 623.2187, 624.2217, 




  √ 
97 14.39 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1008, 161.0218, 297.0974, 
249.0761, 119.0339, 298.1002, 144.9814, 
205.0711, 113.0236, 115.0393, 443.1541, 





 √  
101 14.60 C29H35O15 623.1970 623.1976 0.6 -H 461.1607, 161.0218, 135.0407 PG+Caff+Rha   
Isomer of magnoloside A or 
M or D 
  √ 
Feru-type (3) 
39* 8.23 C36H47O20 799.2663 799.2661 0.2 -H 623.2175, 477.1576, 461.1651, 315.1044, 
175.0370 
Magnoloside K* √   
63 9.79 C30H37O15 637.2131 637.2132 0.1 -H 461.1651, 315.1081, 175.0370 
 




No tR (min) Formula m/z (observed) m/z (calc.) Δ (mDa) Adducts (−)-ESI-MS/MS (m/z) Component name B F L 
84 11.88 C52H49O18 961.2968 961.2919 4.9 -H 785.2517, 623.2175, 477.1576, 461.1651, 
315.1081, 175.0370 
PG+Feru+2Glc+Rha  √ √ 
Coum-type (8) 
36* 8.00 C34H43O19 755.2398 755.2399 0.1 -H 609.2053, 477.1620, 315.1081, 145.0273 Magnoloside I* √ √ √ 
45 8.57 C35H45O19 769.2578 769.2555 2.3 -H 623.2175, 477.1620, 315.1008, 145.0273 PG+Coum+Rha+Glc √   
54 9.20 C29H35O14 607.2051 607.2027 2.4 -H 461.1651, 315.1044, 145.0248 PG+Coum+Rha   √ 
72 10.70 C29H35O14 607.2024 607.2027 0.3 -H 461.1672, 315.1082, 145.0260 PG+Coum+Rha √ √ √ 
73 10.71 C41H55O22 899.3153 899.3185 3.2 -H 753.2823, 607.2202, 461.1695, 315.1081, 
145.0248 
PG+Coum+3Rha  √  
83 11.85 C29H35O14 607.2051 607.2027 2.4 -H 461.1651, 315.1044, 145.0248 PG+Coum+Rha √   
88 12.81 C35H45O18 753.2598 753.2606 0.8 -H 607.2253, 461.1607, 315.1008, 145.0248 PG+Coum+2Rha  √  
90 13.04 C29H35O14 607.2051 607.2027 2.4 -H 461.1607, 315.1081, 145.0248 PG+Coum+Rha √   
Vani-type (1) 
51* 9.13 C34H45O20 773.2509 773.2504 0.5 -H 465.1365, 315.1008 magnoloside P* √   
Syr-type (1) 
65* 9.84 C35H47O21 803.2609  803.2610 0.1 -H 495.1485, 315.1044, 135.0407 magnoloside O* √   
Others-no substituted aromatic acid (5) 
1 1.95 C14H19O8 315.1082 315.1080 0.2 -H 135.0428 PG √ √ √ 
2 2.33 C26H39O17 623.2175 623.2187 1.2 -H 477.1620, 315.1044, 135.0431 PG+Rha+Glc √ √ √ 
3 2.55 C19H27O12 447.1499 447.1503 0.4 -H 315.1044, 135.0407 PG+Api √   
4 2.73 C20H29O12 461.1651 461.1659 0.8 -H 315.1044, 135.0407 PG+Rha √   
5* 2.96 C14H19O7 299.1118 299.1131 1.3 -H 137.0618, 119.0457 salidroside* √   
UNIFI (28) 
24 6.51 C40H53O25 933.2894 933.2876 1.8 -H 771.2360, 609.2003, 477.1620, 315.1008, 
161.0218 
PG+Caff+2Glc+Api √   
26 6.66 C29H35O16 639.1948 639.1925 2.3 -H 477.1576, 161.0218,135.0407 PG+Caff+Glc √   
37 8.12 C44H59O28 1035.3234 1035.3193 4.1 -H 873.3036, 477.1576, 315.1008, 161.0218 PG+Caff+Glc+3Api √ √  
40 8.38 C35H45O19 769.2578 769.2555 2.3 -H 607.2253, 461.1651, 161.0218 PG+Caff+2Rha √ √  
41 8.39 C34H43O19 755.2398 755.2399 0.1 -H 609.2053, 477.1576, 161.0218 PG+Coum+Glc+Api √ √ √ 
47 8.63 C41H55O25 947.3075 947.3032 4.3 -H 785.2517, 623.2175, 477.1576, 315.1044, 
162.0218, 135.0407 
PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
 √  
48 8.76 C35H45O20 785.2517 785.2504 1.3 -H 623.2072, 477.1576, 161.0218, 135.0407 PG+Caff+Glc+Rha √   
49 8.9 C35H45O19 769.2534 769.2555 2.1 -H 607.2225, 461.1641, 161.0208 PG+Caff+2Rha √ √  
50 8.95 C36H47O20 799.2663 799.2661 0.2 -H 623.2175, 477.1576, 315.1044, 175.0370, 
135.0407 
PG+Feru+Rha+Glc √   
52 9.15 C42H57O27 993.3040 993.3087 4.7 +HCOO 785.2460, 623.2225, 461.1695, 315.1044, 
161.0218 
PG+Caff+2Glc+Rha √   
53 9.15 C29H35O14 607.2051 607.2027 2.4 -H 461.1651, 315.1044, 145.0248 PG+Coum+Rha √   




No tR (min) Formula m/z (observed) m/z (calc.) Δ (mDa) Adducts (−)-ESI-MS/MS (m/z) Component name B F L 
60 9.69 C42H57O25 961.3158 961.3189 3.1 -H 785.2517, 623.2175, 477.1397, 315.1081, 
175.0342 
PG+Feru+Rha+2Glc  √  
62 9.76 C41H55O23 915.3125 915.3134 0.9 -H 769.2805, 623.2175, 477.1486, 461.1695, 
315.1081, 161.0218, 135.0407 
PG+Coum+2Rha+Glc √   
67 10.13 C29H35O15 623.1965 623.1976 1.1 -H 461.1651, 315.1044, 161.0208 Plantalloside isomer
14 
PG+Caff+Rha 
√ √ √ 
69 10.54 C29H35O15 623.1965 623.1976 1.1 -H 461.1651, 315.1044, 161.0208 PG+Caff+Rha 
Isomer of magnoloside A or 
M or D 
√   
70 10.57 C41H55O25 947.3012 947.3032 2.0 -H 785.2460, 623.2175, 477.1620, 161.0218 PG+Caff+2Glc+Rha 
Isomer of magnoloside N 
√   
74 10.76 C29H35O14 607.2023 607.2027 0.4 -H 461.1641, 315.1119, 145.0265 PG+Coum+Rha √   
77 11.16 C29H35O15 623.1965 623.1976 1.1 -H 461.1651, 315.1044, 161.0208 PG+Caff+Rha  Isomer of 
magnoloside A or M or D 
√ √ √ 
78 11.27 C35H45O18 753.2638 753.2606 3.2 -H 591.2267, 445.1790, 283.1172, 161.0208, 
135.0417 
BG+Caff+Rha+Glc √   
81 11.57 C29H35O14 607.2023 607.2027 0.4 -H 461.1641, 315.1119, 145.0265 PG+Coum+Rha √   
86 12.51 C30H37O15 637.2153 637.2132 2.1 -H 461.1651, 315.1081, 175.0361 PG+Feru+Rha √   
87 12.66 C35H45O18 753.2638 753.2606 3.2 -H 591.2318, 445.1703, 299.1183, 161.0208, 
135.0417 
LG+Caff+2Rha   √ 
95 14.00 C45H61O28 1049.3353 1049.3349 0.4 -H 887.3353, 315.1117, 161.0218, 135.0407 PG+Caff+2Api+Rha+Glc √   
96 14.29 C29H35O15 623.1970 623.1976 0.6 -H 461.1651, 315.1008, 161.0218 Plantalloside isomer
14 
PG+Caff+Rha 
√ √ √ 
98 14.43 C39H51O23 887.2864 887.2821 4.3 -H 725.2885, 461.1695, 315.1044, 161.0218, 
135.0407 
PG+Caff+2Api+Rha  √  
99 14.43 C29H35O15 623.1970 623.1976 0.6 -H 461.1695, 315.1044, 161.0218 Plantalloside isomer
14 
PG+Caff+Rha 
√ √ √ 
100 14.53 C39H51O23 887.2803 887.2821 1.8 -H 725.2775, 579.2214, 447.1499, 315.1044, 
161.0218, 135.0407 
PG+Caff+2Api+Rha √ √  
Serial number of compounds was labeled according to the corresponding retention time. 
*: The components confirmed by comparison with the reference standards. 
√: The components identified in a part of M. officinalis. B: bark; F: flower; L: leaf. 
Caff: caffeoyl; Coum: coumaroyl; Feru: feruloyl; Glc: glucopyranosyl; All: allopyranosyl; Rha: rhamnopyranosyl; Api: apiofuranosyl; PG: hydroxytyrosol plus Glc/All; 
LG: p-tyrosol plus Glc/All; BG: dehydroxytyrosol plus Glc/All. 
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DISCUSSION AND CONCLUSIONS 
 
Firstly, ten PhGs (M1-7, M12-14) and seven phenolic glycosides (M8-11, M15-17), totally 
eleven novel compounds, were isolated and characterized from MO. Above all, the most 
common forms were the allopyranosides, which are rare in the plant kingdom. But in addition to 
the PhGs with allose as core sugar isolated from the stem bark of MO [41], other PhGs with 
allose as core sugar were also found from the fruit of MOB (for example, crassifolioside, 
magnoloside IIIa and magnoloside IVa) [9], the bark and fruit of M. obovate (for example, 
magnolosides A-C) [91-93], the leaf of M. hodgsonii (for example, hodgsonialloside A-C) [94], 
the leaf of Sanango racemosum (for example, 2-(3,4-dihydroxyphenyl) ethyl 
3-caffeoyl-β-allopyranoside) [95], the liverwort Marchantia polymorpha [96] and the fronds of 
Trichomanes reniforme [97]. 
Secondly, most evaluated PhGs showed good α-glucosidase inhibitory effects with IC50 values 
ranging between 0.13 and 0.75 mM and moderate cytotoxicity against human cancer cell lines 
MGC-803 and HepG2 with IC50 values of 14.60~54.00 μM, 29.53~63.82 μM, respectively. 
Diabetes and cancers are now very common worldwide with a high prevalence and have strongly 
influenced patient’s quality of life, work performance and family relationships, as well as being 
highly expensive for healthcare. Although MOC is traditionally used for the treatment of 
abdominal distention and pain, dyspepsia, and asthmatic cough, the aqueous and MeOH extract 
of MO were also showed anti-tumor activity based on the modern pharmacological studies, 
meanwhile, the anti-tumor activity also belonged to the single constituents of magnolol, honokiol 
as well as PhGs. What’s more, the PhGs were also indicated α-glucosidase inhibitory, so in this 
current study, both the α-glucosidase inhibitory effect and cytotoxicity were tested. 
Thirdly, a 2LC-ECD system with high sensitivity has been developed to simultaneously 
determine seven PhGs in MOC for the first time. Combined the 2LC-ECD determination data 
and multivariable analysis, magnolosides D and M were found the important variables to help 
discriminate the MOC samples of Chuan po and Wen po from nine major habitats.  
Although they were the homologous PhGs, a multi LC-ECD system using an SV was still 
established to determine all the analytes classified into two groups. Magnolosides B, F, and H 
with three sugars in the structures were in group I, while magnolosides A, D, L, and M with two 
sugars in the structures were in group II. The structures of magnolosides A, D, L, and M are 
almost the same except that the linkage sites of the caffeoyl moiety are different. The 
hydrophilicities of group I were higher than that of group II, however, magnolosides A and L 
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were eluted with group I. The caffeoyl moiety linked to 3-C of the core sugar contributes to the 
hydrophilicity of the PhGs compared with those of linked to 4/6-C of the core sugar, therefore 
the elution times of magnolosides A and L were faster than that of magnolosides D and M in the 
above isocratic LC-ECD. Besides, several different channel connection designs of an LC-ECD 
system established by our research group were investigated to obtain an optimal 
chromatographic system to analyze PhGs, however, the satisfying resolution of some PhGs was 
not available in both of the two previous systems due to their close hydrophilicity. Thus the 
present 2LC-ECD system shown in Fig. 3.3 was finally adopted in this study. 
Chemical studies regarding the effect of habitat and variety on MOC were mainly based on the 
profile of magnolol and honokiol [84-87]. The total content of magnolol and honokiol (TMH) in 
MO produced in Hubei was generally higher than that of the same variety from other habitats, 
and the TMH in MOB produced in Zhejiang was lower than that of the same variety from other 
habitats [84], which indicated that the contents of TMH in MOC from different habitats were 
different. Considering the TMH in MO and MOB samples from different habitats were different, 
the current study was focused on another type of main compounds of PhGs, which were newly 
found and rarely studied, to compare the chemical difference between Chuan po and Wen po. 
Based on the research of materia medica of MOC, Chuan po was traditionally regarded as the 
Daodi medicinal materials. The geo-herbalism was the guarantee for the high-quality of TCMs, 
and the Daodi medicinal material was one of the superior medicines. Although the active 
ingredients or the marker components were the important index to evaluate the quality of TCMs, 
it is hardly to objectively and comprehensively evaluate the intrinsic quality of TCM only using 
several indicators, meanwhile, the geo-herbalism doesn’t mean that the components existed in 
Daodi medicinal materials with higher content [98]. So the current study just tried to compare 
and further discover the chemical difference between Chuan po and Wen po. As a result, 
magnolosides D and M, of which the contents were abundant in Chuan po compared with those 
in Wen po, were found the most discriminant components between Chuan po and Wen po from 
the nine major habitats. 
Lastly, a targeted scanning of DINL was established to rapidly characterize PhGs from MOC, 
and 101 PhGs were identified or putatively characterized from MOC, of these, 17 PhGs were 
unambiguously identified by comparing the retention time and MS
E
 data with those of reference 
compounds. The qualitative analysis about the PhGs showed that there were abundant PhGs 
distributed in the stem bark, flower and leaf of MOC and the PhGs were mainly Caff-, Feru-, 
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